ParkerVision (PRKR) 10-K 1 Apr 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 29, 2020	Jun. 29, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Entity Registrant Name	PARKERVISION INC
Entity Central Index Key	0000914139
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Trading Symbol	prkr
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Public Float			$ 16,140,726
Entity Common Stock, Shares Outstanding		30,637,591

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 1,527	$ 354
Restricted cash equivalents		1,000
Available-for-sale securities		26
Accounts receivable, net of allowance for doubtful accounts of $0 and $3 at December 31, 2018 and 2017, respectively	2	27
Inventories, net	98	1,025
Prepaid expenses	538	1,002
Other current assets	55	9
Held for sale assets	65
Total current assets	2,285	3,443
Property and equipment, net	129	376
Intangible assets, net	3,902	5,076
Other assets, net	15	15
Total assets	6,331	8,910
CURRENT LIABILITIES:
Accounts payable	655	678
Accrued expenses:
Salaries and wages	122	376
Professional fees	493	2,054
Other accrued expenses	563	238
Related party note payable, current portion	37	294
Secured note payable	2,400
Lease payable, current portion	86
Deferred revenue		19
Total current liabilities	4,356	3,659
LONG-TERM LIABILITES:
Secured contingent payment obligation	25,557	15,896
Convertible notes, net	837
Related party note payable, net of current portion	799	531
Lease payable, net of current portion	91
Other long term liabilities	1	68
Total long-term liabilities	27,285	16,495
Total liabilities	31,641	20,154
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' DEFICIT:
Common stock, $.01 par value, 75,000 and 30,000 shares authorized, 28,677 and 21,222 issued and outstanding at December 31, 2018 and 2017, respectively	287	212
Warrants outstanding	1,810	826
Additional paid-in capital	364,885	359,141
Accumulated deficit	(392,292)	(371,423)
Total shareholders' deficit	(25,310)	(11,244)
Total liabilities and shareholders' deficit	$ 6,331	$ 8,910

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Consolidated Balance Sheets [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 0	$ 3
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	30,000,000
Common stock, shares issued	28,677,000	21,222,000
Common stock, shares outstanding	28,677,000	21,222,000

Consolidated Statements Of Comp

Consolidated Statements Of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue	$ 135	$ 100
Loss on impairment of inventory	1,134	125
Gross margin	(1,102)	(100)
Research and development expenses	2,875	4,344
Selling, general and administrative expenses	10,427	14,061
Restructuring expenses	690
Total operating expenses	13,992	18,405
Interest and other income	2	26
Interest and other expense	(116)	(69)
Change in fair value of contingent payment obligation	(5,661)	(711)
Total interest and other	(5,775)	(754)
Net loss before income tax	(20,869)	(19,259)
Income tax expense
Net loss	(20,869)	(19,259)
Other comprehensive income, net of tax
Comprehensive loss	$ (20,869)	$ (19,259)
Basic and diluted net loss per common share	$ (0.85)	$ (1.09)
Weighted average common shares outstanding	24,429	17,688
Licensing [Member]
Revenue
Cost of sales
Product [Member]
Revenue	135	100
Cost of sales	$ 103	$ 75

Consolidated Statements Of Shar

Consolidated Statements Of Shareholders Deficit - USD ($) $ in Thousands	Common Stock [Member]	Warrants Outstanding [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2016	$ 132	$ 826	$ 343,087	$ (352,164)	$ (8,119)
Issuance of common stock and warrants in public and private offerings, net of issuance costs	73		13,606		13,679
Issuance of common stock for services	3		422		425
Share-based compensation, net of shares withheld for taxes	4		2,026		2,030
Comprehensive loss for the year				(19,259)	(19,259)
Balance at Dec. 31, 2017	212	826	359,141	(371,423)	(11,244)
Issuance of common stock and warrants in public and private offerings, net of issuance costs	45	1,950	3,281		5,276
Exercise Of Warrants	20	(475)	455
Expiration of warrants		(491)	491
Issuance of convertible debt with beneficial conversion feature			442		442
Issuance of common stock upon conversion and payment of interest in kind on convertible debt	4		52		56
Share-based compensation, net of shares withheld for taxes	6		1,023		1,029
Comprehensive loss for the year				(20,869)	(20,869)
Balance at Dec. 31, 2018	$ 287	$ 1,810	$ 364,885	$ (392,292)	$ (25,310)

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (20,869)	$ (19,259)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,209	1,301
Share-based compensation	1,050	2,164
Loss on disposal of equipment and other assets	489	85
Write down of obsolete inventory	1,134	125
Realized (gain) loss on available-for-sale securities		(9)
Changes in fair value of contingent payment obligation	5,661	711
Changes in operating assets and liabilities:
Accounts receivable	25	(26)
Inventories	(207)	(980)
Prepaid expenses and other	62	84
Accounts payable and accrued expenses	1,034	1,744
Lease payable	115
Total adjustments	10,572	5,199
Net cash used in operating activities	(10,297)	(14,060)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of available-for-sale securities		(4,813)
Proceeds from redemption of available-for-sale securities	26	4,810
Proceeds from sale of assets	50	18
Purchases of property and equipment	(5)	(252)
Payments for patent costs and other intangible assets	(16)	(61)
Net cash provided by (used in) investing activities	55	(298)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants in public and private offerings	5,276	13,679
Net proceeds from debt financings	5,294	1,000
Shares withheld for payment of taxes	(21)	(134)
Debt repayments	(132)
Principal payments on capital lease obligation	(2)	(2)
Net cash provided by financing activities	10,415	14,543
NET CHANGE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH EQUIVALENTS	173	185
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH EQUIVALENTS, beginning of year	1,354	1,169
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH EQUIVALENTS, end of year	1,527	1,354
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	39	69
Cash paid for income taxes
SUPPLEMENTAL SCHEDULE OF NON-CASH ACTIVITIES:
Payment of interest in kind on convertible notes	$ 26
Purchase of equipment under capital lease		$ 6

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Significant Accounting Policies [Abstract]
Significant Accounting Policies	1. SIGNIFICANT ACCOUNTING POLICIES  ParkerVision, Inc. and its wholly-owned German subsidiary, ParkerVision GmbH (collectively “ParkerVision”, “we” or the “Company”) is in the business of innovating fundamental wireless hardware and software technologies and products. We have designed and developed proprietary radio frequency (“ RF ”) technologies for use in semiconductor circuits for wireless communication products. We believe certain patents protecting our proprietary technologies have been broadly infringed by others and therefore our business plan includes enforcement of our intellectual property rights through patent infringement litigation and licensing efforts . We have also designed and developed a consumer distributed WiFi product line that is being marketed under the brand name Milo ® .  We restructured our operations during the third quarter of 2018 in order to reduce operating expenses in light of our limited capital resources. As a result, our primary business is to support and defend the investments we have made in developing and protecting our technologies by focusing on our patent enforcement program. We have determined that our business currently operates under a single operating and reportable segment.  Basis of Presentation Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Certain reclassifications have been made to prior period amounts to conform to the current period presentation. The consolidated financial statements include the accounts of ParkerVision, Inc. and our wholly-owned German subsidiary, ParkerVision GmbH , after elimination of all intercompany transactions and accounts.  Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The more significant estimates made by us include projected future cash flows and risk-adjusted discount rates for estimating the fair value of our secured contingent payment obligation, the volatility and estimated lives of share-based awards used in the estimate of the fair market value of share-based compensation, the assessment of recoverability of long-lived assets, the amortization periods for intangible and long-lived assets, and the valuation allowance for deferred taxes. Actual results could differ from the estimates made. We periodically evaluate estimates used in the preparation of the financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation.  Cash, Cash Equivalents, and Restricted Cash Equivalents We consider cash and cash equivalents to include cash on hand, interest-bearing deposits, overnight repurchase agreements and investments with original maturities of three months or less when purchased. Restricted cash equivalents represent money market investments that are restricted for specific use in payment of legal fees and expenses related to certain of our patent infringement actions. The restricted money market investments have weighted average maturities of three months or less when purchased and are recorded at fair value. We have determined that the fair value of our restricted money market investments fall within Level 1 in the fair value hierarchy (see Note 8).  Inventory Inventory is stated at the lower of actual cost, as determined under the first-in, first-out method, or estimated net realizable value. We review our inventory for estimated obsolescence or unmarketable inventory and write down inventory for the difference between cost and estimated market value based upon assumptions about future demand. Future demand is affected by market conditions, technological obsolescence, new products and strategic plans, each of which is subject to change.  Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined using the straight-line method over the following estimated useful lives:      Manufacturing and office equipment 5 -7 years  Leasehold improvements Shorter of useful life or remaining life of lease  Furniture and fixtures 7 years  Computer equipment and software 3 -5 years  The cost and accumulated depreciation of assets sold or retired are removed from their respective accounts, and any resulting net gain or loss is recognized in the accompanying consolidated statements of comprehensive loss. The carrying value of long-lived assets is reviewed on a regular basis for the existence of facts, both internally and externally, that may suggest impairment. Recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the assets exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the assets.  Intangible Assets Patents, copyrights and other intangible assets are amortized using the straight-line method over their estimated period of benefit. We estimate the economic lives of our patents and copyrights to be fifteen to twenty years. We estimate the economic lives of other intangible assets, including licenses, based on estimated technological obsolescence, to be two to five years, which is generally shorter than the contractual lives. Management evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that may warrant revised estimates of useful lives or that may indicate impairment exists.  Secured Contingent Payment Obligation We have accounted for our secured contingent repayment obligation as long-term debt in accordance with Accounting Standards Codification (“ ASC ”) 470-10-25, “Sales of Future Revenues or Various other Measures of Income.” Our repayment obligations are contingent upon the receipt of proceeds from patent enforcement and/or patent monetization actions. We have elected to measure our secured contingent payment obligation at its fair value in accordance with ASC 825, “Financial Instruments” based on the variable and contingent nature of the repayment provisions. We have determined that the fair value of our secured contingent payment obligation falls within Level 3 in the fair value hierarchy which involves significant estimates and assumptions including projected future patent-related proceeds and the risk-adjusted rate for discounting future cash flows (see Note 8). Actual results could differ from the estimates made. Changes in fair value, including the component related to imputed interest, are included in the accompanying consolidated statements of comprehensive loss under the heading “Change in fair value of contingent payment obligation”.  Leases Our facilities are leased under operating leases. For those leases that contain rent escalations or rent concessions, we record the total rent payable during the lease term on a straight-line basis over the term of the lease with the difference between the rents paid and the straight-line rent recorded as a deferred rent liability in the accompanying consolidated balance sheets.  In February 2016, the FASB established ASC 842, “Leases” by issuing ASU 2016-02 to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. ASC 842 was subsequently amended by ASU 2018-01, ASU 2018-10 and ASU 2018-11 which provided practical expedients for adoption of ASC 842. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. ASC 842 is effective for interim and annual periods beginning after December 15, 2018. A modified retrospective transition approach is required for adoption, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either the effective date or the beginning of the earliest comparative period presented in the financial statements as its date of initial application.  ASC 842 will be effective for us as of January 1, 2019, and we have elected to use the effective date as the initial application date. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and period prior to January 1, 2019. The new standard provides a number of practical expedients in transition and we expect to elect the package of practical expedients which permits us not to reassess under the new standard our prior conclusions about lease identification, lease classification and treatment of initial direct costs. We expect the adoption of this new standard to result in the recognition of operating lease right-to-use assets and operating lease liabilities of approximately $0.56 million and $0.61 million, respectively, primarily related to our facilities leases. In addition, adoption of the new standard will result in significant new disclosures about our leasing activities.  Revenue Recognition As of January 1, 2018, we adopted ASC 606, “Revenue from Contracts with Customers” which implements a common revenue standard that clarifies the principles for recognizing revenue. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The adoption of ASC 606 had no material effect on our consolidated financial statements .  We derive revenue from licensing of our intellectual property, settlements from patent infringement disputes and sales of products. The timing of revenue recognition and the amount of revenue recognized depends upon a variety of factors, including the specific terms of each arrangement and the nature of our deliverables and obligations. In general, we recognize revenue when the performance obligations to our customers have been met. For the sale of products, the performance obligation is generally met at the time product is delivered to the customer. Estimated product returns are deducted from revenue and recorded as a liability. Revenue from the sale of our products includes shipping and handling charged to the customer. Product revenue is recorded net of sales tax collected from customers, discounts, and actual and estimated future returns.  The consideration received from patent license and settlement agreements is allocated to the various elements of the arrangement to the extent the revenue recognition differs between the elements of the arrangement. Elements related to past and future royalties as well as elements related to settlement will be recorded as revenue in our consolidated statements of comprehensive loss when our performance obligations related to each element have been met.    Shipping and Handling Costs Shipping and handling costs related to product sales for the years ended December 31, 2018 and 2017 were approximately $12,000 and $5,000 , respectively. These costs are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.  Advertising Expense Advertising costs are expensed as incurred. Advertising expenses of approximately $0.7 million and $0.4 million for the years ended December 31, 2018 and 2017, respectively, are included in selling, general, and administrative expenses in the accompanying consolidated statements of comprehensive loss.  Research and Development Expenses Research and development costs are expensed as incurred and include salaries and benefits, costs paid to third party contractors, prototype expenses, an allocated portion of facilities costs, maintenance costs for software development tools, and depreciation.  Accounting for Share-Based Compensation We have various share-based compensation programs which provide for equity awards including stock options, restricted stock units (“ RSUs ”) and restricted stock awards (“ RSAs ”). We calculate the fair value of employee share-based equity awards on the date of grant and recognize the calculated fair value as compensation expense over the requisite service periods of the related awards. We estimate the fair value of stock option awards using the Black-Scholes option valuation model. This valuation model requires the use of highly subjective assumptions and estimates including how long employees will retain their stock options before exercising them and the volatility of our common stock price over the expected life of the equity award. Such estimates, and the basis for our conclusions regarding such estimates, are outlined in detail in Note 12. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards. We account for forfeitures of share-based awards as they occur.  As of January 1, 2018, we adopted ASU No. 2017-09, “Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.” This update provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. The adoption of this guidance did not have a material effect on our consolidated financial statements.  Income Taxes The provision for income taxes is based on loss before taxes as reported in the accompanying consolidated statements of comprehensive loss. Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when, based on available objective evidence, it is more likely than not that the benefit of such assets will not be realized. Our deferred tax assets exclude unrecognized tax benefits which do not meet a more-likely-than-not threshold for financial statement recognition for tax positions taken or expected to be taken in a tax return.  On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “ Tax Act ”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease to 21% effective for tax years beginning after December 31, 2017.  Loss per Common Share Basic loss per common share is determined based on the weighted-average number of common shares outstanding during each year. Diluted loss per common share is the same as basic loss per common share as all potential common shares are excluded from the calculation, as their effect is anti-dilutive.  The number of shares underlying outstanding options, warrants, unvested RSUS and convertible notes at December 31, 2018 and 2017 were as follows (in thousands):     2018 2017  Options outstanding 1,228 1,007  Warrants outstanding 13,279 420  Unvested RSUs 14 521  Shares underlying convertible notes 2,746 -  17,267 1,948   These potential shares were excluded from the computation of diluted loss per share as their effect would have been anti-dilutive.

Liquidity And Going Concern

Liquidity And Going Concern	12 Months Ended
	Dec. 31, 2018
Liquidity And Going Concern [Abstract]
Liquidity And Going Concern	2. LIQUIDITY AND GOING CONCERN  The accompanying consolidated financial statements as of and for the year ended December 31, 2018 were prepared assuming we will continue as a going concern, which contemplates that we will continue in operation and will be able to realize our assets and settle our liabilities and commitments in the normal course of business for a period of at least one year from the issuance date of these financial statements. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that could result should we be unable to continue as a going concern.  We have incurred significant losses from operations and negative cash flows in every year since inception and have utilized the proceeds from the sales of our equity and equity-linked securities and our contingent funding arrangements with third-parties to fund our operations, including our litigation costs. For the year ended December 31, 2018, we incurred a net loss of approximately $ 20.9 million and negative cash flows from operations of approximately $1 0.3 million. At December 31, 2018, we had a working capital deficit of approximately $2.1 million and an accumulated deficit of approximately $3 92.3 million. These circumstances raise substantial doubt about our ability to continue to operate as a going concern for a period of one year after the issuance date of these consolidated financial statements.  At December 31, 2018, we had cash and cash equivalents of approximately $1.5 million. In addition, during the first quarter of 2019, we received net proceeds of approximately $1.3 million from the issuance of additional convertible debt securities. In August 2018, we implemented cost reduction measures and ceased ongoing chip development activities and significantly curtailed our spending for sales and marketing of our WiFi product line in order to focus our limited resources on our patent enforcement program. We expect to sell or otherwise exit the Milo product operations the second quarter of 2019 and intend to focus our resources solely on licensing and enforcement of our wireless technologies. However, although we may receive proceeds from our patent enforcement actions in 2019, the timing and amount of such proceeds, if any, are difficult to predict and there can be no assurance we will receive any proceeds from these enforcement actions. In addition, we have approximately $2.4 million in debt obligations due to be repaid in 2019.  Our ability to meet our liquidity needs for the twelve months after the issuance date of these financial statements is dependent upon one or more of (i) our ability to successfully negotiate licensing agreements and/or settlements relating to the use of our technologies by others in excess of our contingent payment obligations to legal counsel; and/or (ii) our ability to raise additional capital from the sale of equity securities or other financing arrangements. We anticipate that we will continue to invest in patent protection and licensing and enforcement of our wireless technologies. We expect that revenue generated from patent enforcement actions, and technology licenses over the twelve months after the issuance date of these financial statements, if any, after deduction of payment obligations to Brickell and legal counsel, may not be sufficient to cover our operating expenses. In the event we do not generate revenues, or other patent-asset proceeds, sufficient to cover our operational costs and contingent repayment obligation, we will be required to raise additional working capital through the sale of equity securities or other financing arrangements.  The long-term continuation of our business plan is dependent upon our ability to secure sufficient financing to support our business, and our ability to generate revenues and/or patent-related proceeds sufficient to offset expenses and meet our contingent payment obligation and other long-term debt repayment obligations. Failure to generate sufficient revenues, raise additional capital through debt or equity financings, and/or reduce operating costs could have a material adverse effect on our ability to meet our short and long-term liquidity needs and achieve our intended long-term business objectives.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2018
Inventories [Abstract]
Inventories	3. INVENTORIES  Inventories consisted of the following at December 31, 2018 and 2017 (in thousands):     2018 2017  Raw materials $ 139 $ 573  Work-in-process - -  Finished goods 941 452  1,080 1,025  Inventory reserves (982) -  98 1,025  During the years ended December 31, 2018 and 2017, we recognized impairment charges to reduce our excess and obsolete inventories to their net realizable values. The following table provides a reconciliation of our inventory reserves for the years ended December 31, 2018 and 2017, respectively (in thousands):     2018 2017  Inventory reserves at beginning of year $ - $ -  Impairment charges 1,134 125  Write down of impaired inventories (152) (125)  Inventory reserves at end of year $ 982 $ -   

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2018
Prepaid Expenses [Abstract]
Prepaid Expenses	 4. PREPAID EXPENSES  Prepaid expenses consisted of the following at December 31, 2018 and 2017 (in thousands):     2018 2017  Prepaid services $ 252 $ 253  Prepaid bonds for German statutory costs 199 62  Prepaid licenses, software tools and support 51 404  Prepaid inventory and production tooling - 121  Prepaid advertising - 75  Prepaid insurance 19 54  Other prepaid expenses 17 33  $ 538 $ 1,002  In 2018, we recorded impairment charges of approximately $0.4 million related to prepaid licenses and production tooling as a result of the restructuring of our operations. These charges are included in “Restructuring expenses” in the accompanying statements of comprehensive loss (see Note 13).

Property And Equipment, Net

Property And Equipment, Net	12 Months Ended
	Dec. 31, 2018
Property And Equipment, Net [Abstract]
Property And Equipment, Net	5. PROPERTY AND EQUIPMENT, NET  Property and equipment, at cost, consisted of the following at December 31, 2018 and 2017 (in thousands):    2018 2017  Equipment and software, including equipment purchased under capital leases of $17 and $297 at December 31, 2018 and 2017, respectively $ 1,555 $ 6,556  Leasehold improvements 786 786  Furniture and fixtures 182 185  2,523 7,527  Less accumulated depreciation, including accumulated depreciation for equipment purchased under capital leases of $13 and $206 at December 31, 2018 and 2017, respectively (2,394) (7,151)  $ 129 $ 376   Depreciation expense related to property and equipment was approximately $0.13 million and $0.15 million in 2018 and 2017, respectively. Depreciation expense includes depreciation related to capital leases of approximately $0.002 million and $0.05 for the periods ended December 31, 2018 and 2017, respectively. Our capital leases have original terms of one to three years. The principal payments for these capital leases are reflected as cash outflows from financing activities in the accompanying consolidated statements of cash flows. Future minimum lease payments under our capital leases that have initial terms in excess of one year are included in “Contractual Obligations” in Note 10.  In connection with the closure of our Lake Mary facility in 2018, we reclassified equipment with a net book value of approximately $0.07 million to assets held for sale. We have contracted with a third party for the consignment sale of these assets and anticipate completion of the sale within 12 months. For the year ended December 31, 2018, we recognized a gain on the sale of assets held for sale of approximately $0.01 million which is included in selling, general and administrative expenses in the accompanying statements of comprehensive loss.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2018
Intangible Assets [Abstract]
Intangible Assets	6. INTANGIBLE ASSETS  Intangible assets consisted of the following at December 31, 2018 and 2017 (in thousands):    2018 2017   Patents and copyrights $ 18,350 $ 19,324  Less accumulated amortization (14,448) (14,248)  $ 3,902 $ 5,076   Amortization expense for each of the years ended December 31, 2018 and 2017 was approximately $1.1 million and $1.2 million, respectively. For each of the years ended December 31, 2018 and 2017, we recorded losses on the disposal of intangible assets of approximately $0.1 million.  Future estimated amortization expense for intangible assets that have remaining unamortized amounts as of December 31, 2018 is as follows (in thousands):      2019 $ 713  2020 520  2021 448  2022 406  2023 359  2024 and thereafter 1,456  Total $ 3,902 

Debt

Debt	12 Months Ended
	Dec. 31, 2018
Debt [Abstract]
Debt	7. DEBT  Notes Payable Notes payable at December 31, 2018 and 2017, consisted of the following (in thousands):      Description 2018 2017  Note payable to a related party $ 836 $ 825  Secured note payable 2,400 -  Total notes payable 3,236 825  Less current maturities 2,437 294  Long-term note payable $ 799 $ 531   Note Payable to a Related Party The note payable to a related party represents an unsecured promissory note to Sterne, Kessler, Goldstein, & Fox, PLLC (“ SKGF ”), a related party (see Note 14) upon conversion of outstanding and unpaid legal fees of $0.8 million in February 2016. The note had an interest rate of 8% per annum with an original balloon maturity of the outstanding principal balance due on December 31, 2017. In January 2018, we amended the note, retroactive to December 31, 2017 to allow for interest only payments through March 2018 and principal and interest payments through March 31, 2020 . In August 2018, we further amended the note, retroactive to April 30, 2018 to defer principal and interest payments from May 1, 2018 through September 30, 2018. We determined that the amendments to the note constitute modifications of the debt which are accounted for on a prospective basis.  The note, as modified, provided for payments of principal and interest of approximately $48,500 per month commencing October 31, 2018 through March 31, 2020. Failure to comply with the payment terms of this note constitutes an event of default which, if uncured, will result in the entire unpaid principal balance of the note and any unpaid, accrued interest to become immediately due and payable. In addition, the note provides for an increase in the interest rate to 12% per annum in the event of a default.  As of December 31, 2018, we were in default on the payment terms of the SKGF note. In March 2019, we amended the note to provide for a waiver of past payment defaults, a decrease in the interest rate from 8% per annum to 4% per annum, an extension of the maturity date of the note from March 2020 to April 2022 , and a modification of payment terms under the note (see Note 16).   Secured Note Payable The secured note payable represents a non-interest bearing promissory note payable to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (“ Mintz ”) in settlement of outstanding and unpaid legal fees and costs associated with our patent enforcement programs. We paid Mintz an initial installment of $0.1 million upon execution of the note and the remaining balance is payable in monthly installments of $0.2 million commencing November 1, 2018 and continuing until the entire unpaid principal balance is paid. We pledged as security for the note 25 United States (“ U.S. ”) patents and 6 correlating foreign patents that were simultaneously released by Brickell Key Investments LP (“ Brickell ”). The Mintz note accelerates and becomes immediately due and payable in the case of standard events of default or in the event of a sale or other transfer of substantially all of our assets or a transfer of more than 50% of our capital stock in one or a series of transactions or through a merger or other similar transaction. In an event of default, the Mintz note will accrue interest at a rate of 12% per annum on any outstanding balance until such time that the note is paid in full. As of December 31, 2018, we were in default on the payment terms of the Mintz note. The payment default was cured in January 2019. On April 1, 2019, Mintz waived past and future payment defaults under the note through at least May 31, 2019, provided that no other event of default occurs. Mintz also waived acceleration of unpaid principal and interest as well as an increase in the interest rate to the default rate of 12% .  At December 31, 2018, the aggregate maturities of our notes payable, after consideration of the effect of the March 2019 amendment of the SKGF note, are as follows (in thousands):     2019 $ 2,437  2020 90  2021 93  2022 616  Total $ 3,236   The estimated fair value of our notes payable at December 31, 2018 is approximately $3.0 million based on a risk-adjusted discount rate.  Convertible Notes In September 2018, we sold two tranches of five -year promissory notes for aggregate proceeds of approximately $1.3 million, including $0.4 million sold to related parties (see Note 14). The notes are convertible, at the holders’ option, into shares of our common stock at fixed conversion prices. We must repay, in cash, the principal balance of any outstanding, unconverted notes on the five-year anniversary of the issuance date. Accordingly, we have recognized the convertible notes as debt in our consolidated financial statements. The fixed conversion prices of the notes were below market value of our common stock on the closing date resulting in a beneficial conversion feature with a value of approximately $0.4 million. The beneficial conversion feature is recorded as a discount on the convertible notes with a corresponding increase to additional paid in capital.  Convertible notes payable at December 31, 2018 consist of the following (in thousands):     Description Fixed Conversion Rate Effective Interest Rate Maturity Date 2018  Convertible notes dated September 10, 2018 $0.40 8.3% September 7, 2023 $ 800  Convertible notes dated September 19, 2018 $0.57 8.3% September 19, 2023 425  Total principal balance 1,225  Less unamortized discount 388  $ 837   The notes bear interest at a stated rate of 8% per annum. Interest is payable quarterly and we may elect to pay interest in either cash, shares of our common stock, or a combination thereof, subject to certain equity conditions. For the year ended December 31, 2018, we recognized interest expense of approximately $0.05 million, including approximately $0.02 related to amortization of the discount and $0.03 million related to the contractual interest which we elected to pay in shares of our common stock. The unamortized discount on the convertible notes will be amortized over a remaining period of approximately 4.75 years.  At the holders’ option, the convertible notes outstanding at December 31, 2018 could be converted into an aggregate of approximately 2.7 million shares of our common stock based on the fixed conversion prices. For the year ended December 31, 2018, an aggregate of $0.1 million in outstanding principal was converted by the holders into 0.25 million shares of our common stock at a fixed conversion price of $0.40 .  We have the option to prepay the notes any time following the one-year anniversary of the issuance of the notes, subject to a premium on the outstanding principal prepayment amount of 25% prior to the two-year anniversary of the note issuance date, 20% prior to the three-year anniversary of the note issuance date, 15% prior to the four-year anniversary of the note issuance date, or 10% thereafter. The notes provide for events of default that include failure to pay principal or interest when due, breach of any of the representations, warranties, covenants or agreements made by us, events of liquidation or bankruptcy, and a change in control. In the event of default, the interest rate increases to 12% per annum and the outstanding principal balance of the notes plus all accrued interest due may be declared immediately payable by the holders of a majority of the then outstanding principal balance of the notes.  Secured Contingent Payment Obligation The following table provides a reconciliation of our secured contingent payment obligation measured at estimated fair market value for the year ended December 31, 2018 and 2017, respectively (in thousands).       2018 2017  Secured contingent payment obligation, beginning of year $ 15,896 $ 14,185  Proceeds from contingent payment obligation 4,000 1,000  Repayment - -  Change in fair value 5,661 711  Secured contingent payment obligation, end of year $ 25,557 $ 15,896   Our secured contingent payment obligation represents the estimated fair value of our repayment obligation to Brickell under a February 2016 funding agreement, as amended from time to time (the “ CPIA ”). To date, we have received aggregate proceeds of $18 million, including $4.0 million and $1.0 million received in 2018 and 2017, respectively, in exchange for Brickell’s right to reimbursement and compensation from gross proceeds resulting from patent enforcement and other patent monetization actions. To date, we have repaid an aggregate of $3.3 million under the CPIA from patent license and settlement proceeds.  In 2018, we received aggregate proceeds of $4.0 million from Brickell under the CPIA including proceeds of $2.5 million received in December 2018. In connection with the additional proceeds received in December 2018, we issued Brickell a warrant to purchase up to 5.0 million shares of our common stock at an exercise price of $0.16 per share (see Note 11). As the estimated fair value of the payment obligation to Brickell resulting from this additional funding exceeded the $2.5 million in proceeds received, no value was assigned to the warrants. The excess of fair value of over the proceeds received of approximately $0.8 million was included in the change in fair value of our contingent payment obligation in the accompanying consolidated statement of comprehensive loss for the year ended December 31, 2018.  Brickell is entitled to priority payment of 100% of proceeds received from all patent-related actions until such time that Brickell has been repaid in full. After repayment of the funded amount, Brickell is entitled to a portion of remaining proceeds up to a specified minimum return which is determined as a percentage of the funded amount and varies based on the timing of repayment. In addition, Brickell is entitled to a pro rata portion of proceeds from specified legal actions to the extent aggregate proceeds from those actions exceed the specified minimum return.  Brickell holds a senior security interest in the majority of our assets until such time as the specified minimum return is paid, in which case, the security interest will be released except with respect to the patents and proceeds related to specific legal actions. The security interest is enforceable by Brickell in the event that we are in default under the agreement which would occur if (i) we fail, after notice, to pay proceeds to Brickell, (ii) we become insolvent or insolvency proceedings are commenced (and not subsequently discharged) with respect to us, (iii) our creditors commence actions against us (which are not subsequently discharged) that affect our material assets, (iv) we, without Brickell’s consent, incur indebtedness other than immaterial ordinary course indebtedness, or (v) there is an uncured non-compliance of our obligations or misrepresentations under the agreement. As of December 31, 2018, we are in compliance with our obligations under this agreement.  In addition, in the event of a change in control of the Company, Brickell has the right to be paid its return as defined under the CPIA based on the transaction price for the change in control event.  We have elected to measure our secured contingent payment obligation at fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods (see Note 8). The secured contingent payment obligation is remeasured to fair value at each reporting period with changes recorded in the consolidated statements of comprehensive loss until the contingency is resolved.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2018
Fair Value Measurements [Abstract]
Fair Value Measurements	8. FAIR VALUE MEASUREMENTS  ASC 820, “Fair Value Measures” establishes a fair value hierarchy that prioritizes the inputs to valuation methods used to measure fair value. The three levels of the fair value hierarchy are as follows:  · Level 1: Quoted prices for identical assets or liabilities in active markets which we can access · Level 2: Observable inputs other than those described in Level 1 · Level 3: Unobservable inputs  The following table summarizes financial assets and financial liabilities carried at fair value and measured on a recurring basis as of December 31, 2018 and 2017, segregated by classification within the fair value hierarchy (in thousands):     Fair Value Measurements  Total Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)  December 31, 2018:  Liabilities:  Secured contingent payment obligation $ 25,557 $ - $ - $ 25,557    December 31, 2017:  Assets:  Available-for-sale securities $ 26 $ 26 $ - $ -  Restricted cash equivalents 1,000 1,000 - -  Liabilities:  Secured contingent payment obligation 15,896 - - 15,896   For the years ended December 31, 2018 and 2017, respectively, we had no transfers of assets or liabilities between the levels of the hierarchy. We determine the fair value of our available-for-sale securities and restricted cash equivalents using a market approach based on quoted prices in active markets (Level 1 inputs).  In 2016, we recognized a secured contingent payment obligation upon our receipt of proceeds from Brickell for funding of certain patent-related actions . The fair value of the contingent payment obligation at December 31, 2018 and 2017 was estimated at $25.6 million and $15.9 million , respectively. These values were calculated using a probability-weighted income approach based on various cash flow scenarios as to the outcome of patent-related actions both in terms of timing and amount, discounted to present value using a risk-adjusted rate. The contingent payment obligation does not have a fixed duration; however, our cash flow projections assume a duration through 2021. The assumed cash outflows range from $0 to $46 million and the cash flow scenarios have probabilities of 0% to 35% . We used a risk-adjusted discount rate of approximately 16.5% , based on a two year risk-free rate of approximately 2.5% as adjusted by 8% for credit risk and 6% for litigation inherent risk. Changes in any of these Level 3 inputs could result in a higher or lower fair value measurement. For example, a decrease in the risk-adjusted discount rate from 16.5% to 8% would result in an increase in the fair value of approximately $4.6 million. Refer to Note 7 for a reconciliation of our secured contingent payment obligation measured at estimated fair value for the years ended December 31, 2018 and 2017.

Income Taxes And Tax Status

Income Taxes And Tax Status	12 Months Ended
	Dec. 31, 2018
Income Taxes And Tax Status [Abstract]
Income Taxes And Tax Status	9. INCOME TAXES AND TAX STATUS  Our net losses before income taxes for the years ended December 31, 2018 and 2017 are from domestic operations as well as losses from our wholly-owned German subsidiary. We elected to treat our German subsidiary as a disregarded entity for purposes of income taxes and accordingly, the losses from our German subsidiary has been included in our operating results.  No current or deferred tax provision or benefit was recorded in 2018 or 2017 as a result of current losses and fully deferred tax valuation allowances for all periods. We have recorded a valuation allowance to state our deferred tax assets at their estimated net realizable value due to the uncertainty related to realization of these assets through future taxable income. On December 22, 2017, the U.S. government enacted comprehensive tax legislation, the Tax Act. The Tax Act makes broad and complex changes to the U.S. tax code that includes a reduction to the U.S. federal corporate statutory tax rate to 21% effective in 2018. The Securities and Exchange Commission (“ SEC ”) staff issued Staff Accounting Bulletin 118 which provides guidance on accounting for the impact of the Tax Act and states that a reasonable estimate of the Tax Act’s effects on our deferred tax balances should be included in our consolidated financial statements. As of December 31, 2017, our accounting for the income tax effects of the Tax Act was completed and there were no adjustments related to the Tax Act in our reporting period ended December 31, 2018. The federal corporate tax rate reduction created a reduction to our deferred tax assets and liabilities with a corresponding reduction to our valuation allowance.  A reconciliation between the provision for income taxes and the expected tax benefit using the federal statutory rate of 21% and 34 % for the years ended December 31, 2018 and 2017, respectively are as follows (in thousands):     2018 2017  Tax benefit at statutory rate $ (4,382) $ (6,548)  State tax benefit (897) (674)  Impact of the Tax Act - 41,646  Increase (decrease) in valuation allowance 5,304 (34,346)  Research and development credit (51) (129)  Other 26 51  $ - $ -   Our deferred tax assets and liabilities relate to the following sources and differences between financial accounting and the tax bases of our assets and liabilities at December 31, 2018 and 2017 (in thousands):      2018 2017  Gross deferred tax assets:  Net operating loss carry-forward $ 84,192 $ 82,168  Research and development credit 7,879 8,051  Stock compensation 1,027 1,248  Patents and other 1,495 1,427  Contingent payment obligation 2,842 1,409  Inventories 249 -  Fixed assets 25 25  Accrued liabilities 146 49  Deferred rent and lease liabilities 46 20  Charitable contributions 5 7  Deferred revenue - 5  Capital loss carry-forward 3 3  Warranty reserve 4 2  Bad debt expense - 1  97,913 94,415  Less valuation allowance (97,816) (94,415)  97 -  Gross deferred tax liabilities:  Convertible debt (97) -  (97) -  Net deferred tax asset $ - $ -   Approximately $0.1 million, net of tax effect, of unrecognized tax benefit related to the beneficial conversion feature of convertible debt would be recorded as an adjustment to contributed capital rather than a decrease in earnings, if recognized.  At December 31, 2018, we had cumulative net operating loss (“ NOL ”) carry-forwards for income tax purposes of $336.4 million, of which $323.5 million is subject to expiration in varying amounts from 2019 to 2036 . At December 31, 2018, we also had research and development tax credit carryforwards of $7.9 million, which expire in varying amounts from 2019 through 2037 .  Our ability to benefit from the tax credit carry-forwards could be limited under certain provisions of the Internal Revenue Code if there are ownership changes of more than 50%, as defined by Section 382 of the Internal Revenue Code of 1986 (“ Section 382 ”). Under Section 382, an ownership change may limit the amount of NOL, capital loss and R&D credit carry-forwards that can be used annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period. We conduct a study annually of our ownership changes. Based on the results of our studies, we have determined that we do not have any ownership changes on or prior to December 31, 2018 which would result in limitations of our NOL, capital loss or R&D credit carry-forwards under Section 382.  Uncertain Tax Positions We file income tax returns in the U.S. federal jurisdiction and various state jurisdictions. We have identified our Federal and Florida tax returns as our only major jurisdictions, as defined. The periods subject to examination for those returns are the 1998 through 2018 tax years. The following table provides a reconciliation of our unrecognized tax benefits due to uncertain tax positions for the years ended December 31, 2018 and 2017, respectively (in thousands).     2018 2017  Unrecognized tax benefits – beginning of year $ 927 $ 1,370  Impact of the Tax Act - (443)  Unrecognized tax benefits – end of year $ 927 $ 927   Future changes in the unrecognized tax benefit will have no impact on the effective tax rate so long as we maintain a full valuation allowance.  Our policy is that we recognize interest and penalties accrued on any unrecognized tax benefits as a component of our income tax expense. We do not have any accrued interest or penalties associated with any unrecognized tax benefits. For the years ended December 31, 2018 and 2017, we did not incur any income tax-related interest income, expense or penalties.

Commitments And Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments And Contingencies [Abstract]
Commitments And Contingencies	10. COMMITMENTS AND CONTINGENCIES Lease Commitments The following table presents a summary of our facilities under non-cancelable lease agreements at December 31, 2018:      Description Lease Start Date Lease End Date Renewal options remaining Straight line monthly rental payment (in thousands)  Corporate office, Jacksonville, Florida 7/15/2018 7/31/2019 none $ 31  Wireless design facility, Lake Mary, Florida 7/1/2017 11/30/2022 2 options to extend for 36 months each $ 13  Warehouse and production facility, Jacksonville, Florida 7/1/2017 7/31/2020 none $ 2   Deferred rent is amortized to rent expense over the respective lease terms. In addition to sales tax payable on base rental amounts , certain leases obligate us to pay pro-rated annual operating expenses for the properties. Rent expense for our facilities for the years ended December 31, 2018 and 2017 was approximately $0.5 million and $0.6 million, respectively .  Contractual Obligations Future minimum lease payments under all non-cancelable operating leases and capital leases that have initial terms in excess of one year as of December 31, 2018 were as follows (in thousands):     Contractual obligations: 2019 2020 2021 and thereafter Total  Operating leases $ 372 $ 191 $ 345 $ 908  Capital leases $ 2 $ 1 $ - $ 3   Our contractual obligations as of December 31, 2018 for operating leases include approximately $0.7 million related to our Lake Mary, Florida facility. We ceased use of this facility in 2018 and at December 31, 2018, we have recorded a lease liability of $0.2 million which reflects the estimated net present value of our Lake Mary lease obligation, net of estimated future sublease rental income.  Legal Proceedings We are a party to a number of patent enforcement actions initiated by us against others for the infringement of our technologies, as well as counter claims and proceedings brought by others against us in an attempt to invalidate certain of our patent claims. These patent-related proceedings are more fully described below. We have several patent enforcement actions in Germany which has a “loser pay” system whereby the non-prevailing party is responsible for statutory attorney fees and costs. If we determine it is probable that we will have an unfavorable outcome in any of our German cases, we record an estimate of expenses for the probable loss. We received an unfavorable decision from Germany in October 2018, as more fully described below (see Qualcomm v. ParkerVision – Federal Patent Court in Germany ). As a result, for the year ended December 31, 2018, we have recorded an aggregate of $0.1 million in expenses for statutory fees and costs estimated in that case. There is at least a reasonable possibility of an unfavorable outcome in any one or more of our legal proceedings that could result in expenses in the aggregate that could have a material unfavorable impact on our results of operations as more fully discussed below.  ParkerVision v. Qualcomm and HTC (Middle District of Florida) We have a patent infringement complaint pending in the Middle District of Florida against Qualcomm and Qualcomm Atheros, Inc. (collectively “ Qualcomm ”), and HTC (HTC Corporation and HTC America, Inc.) (the “ Qualcomm Action ”) seeking unspecified damages and injunctive relief for infringement of certain of our patents. Certain of the defendants have filed counterclaims against us for non-infringement and invalidity for all patents in the case. A claim construction hearing was held in August 2015 but no ruling on claim construction has been issued by the court. In February 2016, the court granted the parties’ joint motion to stay these proceedings until resolution of the proceedings at the International Trade Commission (“ ITC ”) as discussed below. In May 2017, the stay of these proceedings was continued pending an appeal of certain Patent Trial and Appeal Board (“ PTAB ”) decisions with regard to our U.S. Patent 6,091,940 (“ the ‘940 Patent ”). In September 2018, the Federal Circuit issued its decision in the appeal of the ‘940 Patent as discussed in Qualcomm v. ParkerVision – PTAB below. Accordingly, in January 2019, the court lifted the stay. A trial schedule has not yet been set for this case.  Qualcomm v. ParkerVision -PTAB In August 2015, Qualcomm filed an aggregate of ten petitions for Inter Partes Review (“ IPR ”) with the P TAB seeking to invalidate certain claims related to three of the eleven patents originally asserted in our Qualcomm Action. In March 2016, the PTAB issued decisions denying institution of trial for three of the petitions, all of which relate to our U.S. patent 7,039,372 (“ the ‘372 Patent ”). The remaining petitions, all of which relate to the ‘940 Patent and U.S. patent 7,966,012 (“ the ‘012 Patent ”) were instituted for trial by the PTAB. In May 2016, the PTAB granted our motion to disclaim the challenged claims of the ‘012 Patent and entered an adverse judgment against us with respect to those claims. In March 2017, the PTAB issued its decisions on the six outstanding IPRs, all of which relate to the ‘940 Patent. The PTAB ruled in our favor on three of the six petitions, ruled in Qualcomm’s favor on two of the six petitions and issued a split decision on the claims covered in the sixth petition. As a result of the PTAB decisions, certain claims of the ‘940 Patent were found to be un-patentable and certain claims were found not to be un-patentable. In May 2017, we filed a notice of appeal of these decisions with the United States Court of Appeals for the Federal Circuit (“ CAFC ”). Qualcomm also appealed the decisions that were unfavorable to them. On September 13, 2018, the CAFC upheld the PTAB ruling with regard to the ‘940 Patent. As a result of the ruling, we prevailed with regard to the method claims of the ‘940 Patent and Qualcomm prevailed on the apparatus claims. This matter is now closed although the patents at issue in this proceeding are the subject of the Qualcomm Action discussed above.  ParkerVision v. Apple and Qualcomm (ITC) In December 2015, we filed a complaint with the U.S. ITC against Apple, Inc., LG Electronics, Inc., LG Electronics U.S.A., Inc., and LG Electronics MobileComm U.S.A., Inc. (collectively “ LG ”), Samsung Electronics Co., Ltd., Samsung Electronics America, Inc., and Samsung Semiconductor, Inc. (collectively “ Samsung ”) and Qualcomm alleging that these companies make, use or sell products that infringe certain of our patent claims and requesting that the ITC bar the defendants from continuing to import and sell infringing products in the U.S. We filed a corresponding patent infringement complaint in the Middle District of Florida against these same defendants. In January 2016, the ITC instituted an investigation based on our complaint. In July 2016, we entered into a confidential patent license and settlement agreement with Samsung and, as a result, Samsung was removed from the ITC action. In January 2017, we dismissed three of the four patents from the case in order to simplify the investigation. On March 10, 2017, the administrative law judge issued a ruling on a pre-trial motion that precluded us from presenting key evidence in our case. As a result, on March 13, 2017, we filed a motion to terminate the proceedings at the ITC. On April 28, 2017, the ITC granted our motion to withdraw from the ITC proceedings.  ParkerVision v. Apple and Qualcomm (Middle District of Florida) In December 2015, we filed a patent infringement complaint in the Middle District of Florida against Apple, LG, Samsung and Qualcomm alleging infringement of four of our patents. In February 2016, the district court proceedings were stayed pending resolution of the corresponding case filed at the ITC. In July 2016, we entered into a patent license and settlement agreement with Samsung and, as a result, Samsung was dismissed from the district court action. In March 2017, we filed a motion to terminate the ITC proceedings and a corresponding motion to lift the stay in the district court case. This motion was granted in May 2017. In July 2017, we filed a motion to dismiss LG from the district court case (see ParkerVision v. LG below). Also in July 2017, Qualcomm filed a motion to change venue to the southern district of California and Apple filed a motion to dismiss for improper venue. In March 2018, the district court ruled against the Qualcomm and Apple motions. The parties also filed a joint motion in March 2018 to eliminate three of the four patents in the case in order to expedite proceedings leaving our U.S. patent 9,118,528 as the only remaining patent in this case. A claim construction hearing was held on August 31, 2018, and we are currently awaiting the court’s decision regarding claim language pertinent to this case. We anticipate that a trial date will be scheduled for this proceeding following the court’s order regarding claim construction.  ParkerVision v. LG (District of New Jersey) In July 2017, we filed a patent infringement complaint in the district of New Jersey against LG for the alleged infringement of the same patents previously asserted against LG in the middle district of Florida (see ParkerVision v. Apple and Qualcomm above). We elected to dismiss the case in the middle district of Florida and re-file in New Jersey as a result of a recent Supreme Court ruling regarding proper venue. In March 2018, the court stayed this case pending a final decision in ParkerVision v. Apple and Qualcomm in the Middle District of Florida. As part of this stay, LG has agreed to be bound by the final claim construction decision in that case.  ParkerVision v. LG Electronics (Munich, Germany) In June 2016, we filed a complaint in Munich District Court against LG Electronics Deutschland GmbH, a German subsidiary of LG Electronics, Inc. (“ LGE ”) seeking damages and injunctive relief for the alleged infringement of the German part of our European patent 1 206 831 (“ the ‘831 Patent ”). A hearing in this case was held in November 2016 at which time the court concluded that certain LGE products using Qualcomm RF circuitry infringe our patent. The final decision in this case was stayed pending resolution of the corresponding nullity, or validity, action filed by Qualcomm in the German Federal Patent Court in Munich (see Qualcomm v. ParkerVision below). In October 2018, we received an unfavorable decision in the nullity case for which we have filed an appeal. The outcome of our appeal of the nullity action will determine the outcome of this action. If our appeal is unsuccessful, we will be subject to a claim for reimbursement of statutory attorney’s fees and costs in this case. We estimate a claim of approximately $0.06 million for which we have posted a bond. The cost of the bond is included in “Prepaid expenses” in the accompanying consolidated balance sheets and will be charged to expense if a loss becomes probable.  ParkerVision v. Apple (Munich, Germany) - the Apple I case In October 2016, we filed a complaint in Munich District Court against Apple, Inc., Apple Distribution International, and Apple Retail Germany B.V. & Co. KG (collectively “ Apple ”) seeking damages and injunctive relief for the alleged infringement of the ‘831 Patent (the “ Apple I Case ”). In February 2017, we amended our complaint adding the infringement of a second German patent and alleging infringement by Apple devices that incorporate an Intel transceiver chip. The Munich Regional Court bifurcated the new claims into a second case (see ParkerVision v. Apple - the Apple II case below). A hearing was held in May 2017 in the Apple I Case. In June 2017, the court deferred its ruling pending the decision from the German Federal Patent Court in the validity action filed by Qualcomm (see Qualcomm v. ParkerVision below ). In October 2018, we received an unfavorable decision in the nullity case for which we have filed an appeal. We have not posted a bond to cover the potential statutory costs in this case. In March 2019, the district court declared the complaint withdrawn, a decision we are able to appeal provided we post a bond for approximately $0.1 million by April 2019. If we fail to post a bond or our appeal of the nullity action is unsuccessful, we will be subject to a claim for reimbursement of statutory attorney’s fees and costs of approximately $0.1 million. The accompanying consolidated financial statements do not include any accrual for a loss contingency in this case as the loss is not considered probable as of December 31, 2018.  Qualcomm v. ParkerVision -Federal Patent Court in Germany (as appealed to the German Supreme Court) In August 2016, Qualcomm filed a validity action in Federal Patent Court in Germany against the ’831 Patent. The outcome of this validity action impacts our German patent infringement cases against LGE and Apple as discussed above. On October 17, 2018, following an oral hearing, the court ruled that the ‘831 Patent was invalid. Based on the October 2018 decision from the federal court, we have accrued a contingent loss of $0.1 million for the estimated statutory fees and costs in this case. In January 2019, we appealed this decision to the German Supreme Court. Dates have not yet been established for the appeal. If we ultimately do not prevail in this case, in addition to the contingent loss recorded at December 31, 2018, we will be subject to a claim for reimbursement of statutory attorney fees and costs for the appeal which we estimate to be approximately $0.1 million. In addition, we may be subject to claims for reimbursement of statutory attorney fees and costs for the LG and Apple I cases that are stayed pending this validity decision. We estimate these possible additional costs to be approximately $0.2 million, a portion of which is covered by a $0.06 million bond we have posted in the LG case.  ParkerVision v. Apple (Munich, Germany)- the Apple II case The Apple II case seeks damages and injunctive relief for the alleged infringement of the German part of our European patent 1 135 853 (“ the ‘853 Patent ”). A preliminary hearing was held in November 2017. Subsequent to the hearing, the court requested that we supplement certain elements of the infringement claims against Apple devices. In May 2018, we filed our supplemental briefs as requested by the court. In October 2018, we also filed a supplemental expert report. The court appointed an expert in this case and a hearing was held in March 2019 for purposes of providing expert testimony. The court is expected to rule in April 2019 . We have posted a bond of approximately $0.14 million which is our estimated maximum exposure in this case. The cost of the bond is included in “Prepaid expenses” in the accompanying consolidated balance sheets as of December 31, 2018.  Intel v. ParkerVision (Federal Patent Court in Germany) In August 2017, Intel filed a nullity action in German Federal Patent Court claiming invalidity of the ‘853 Patent that is the subject of the Apple II case. If the ‘853 Patent is declared invalid, we may be subject to a claim for reimbursement of statutory attorney fees and costs in this case which we currently estimate will not exceed $0.1 million. No dates have yet been set in this nullity action, and the accompanying consolidated financial statements do not include any accrual for a loss contingency in this case as a loss is not considered probable as of December 31, 2018.

Stock Authorization And Issuanc

Stock Authorization And Issuance	12 Months Ended
	Dec. 31, 2018
Stock Authorization And Issuance [Abstract]
Stock Authorization And Issuance	11. STOCK AUTHORIZATION AND ISSUANCE Preferred Stock We have 15 million shares of preferred stock authorized for issuance at the direction of the board of directors (the “ Board ”). On November 17, 2005, our Board designated 0.1 million shares of authorized preferred stock as the Series E Preferred Stock in conjunction with its adoption of a Shareholder Protection Rights Agreement. As of December 31, 2018, we had no outstanding preferred stock.  Common Stock We have 75 million shares of common stock authorized for issuance. Our shareholders approved an amendment to our articles of incorporation in 2017 to increase the number of authorized shares of common stock from 20 million to 30 million shares. In addition, on June 12, 2018, our shareholders approved an amendment to our articles of incorporation to increase the number of authorized shares of common stock from 30 million to 40 million shares and on October 30, 2018, our shareholders approved an amendment to our articles of incorporation to increase the number of our authorized shares of common stock from 40 million to 75 million shares.  As of December 31, 2018, we have 14.5 million shares reserved for issuance under outstanding warrants, options and unvested RSUs, 0.3 million shares reserved for future issuance under shareholder approved equity compensation plans, and 6.0 million shares reserved for the payment of interest and conversion of principal under outstanding convertible notes. Stock Issuances The following table presents a summary of completed equity offerings for the years ended December 31, 2018 and 2017 (in thousands, except for per share amounts):     Date Transaction # of Common Shares/ Units Sold Average Price per Share/Unit # of Warrants Issued (in 000’s) Average Exercise Price per Warrant Net Proceeds (1)  July 2018 and September 2018 Offerings under PIPE Agreement - - 10,000 $0.38 $ 1,901  March 2018 Director Stock Purchase 217 $0.83 - - $ 180  March - May 2018 Offerings under ATM 1,359 $0.87 - - $ 1,148  January - June 2018 Offerings under Equity Line Agreement 2,940 $0.70 - - $ 2,047  October - December 2017 Offerings under Equity Line Agreement 773 $1.29 - - $ 958  August - December 2017 Offerings under ATM 2,119 $1.50 - - $ 2,970  February 2017 Director Stock Purchase 81 $2.11 - - $ 170  January - March 2017 Offerings under ATM 4,072 $2.46 - - $ 9,581  (1) After deduction of applicable underwriters’ discounts, placement agent fees, and other offering costs.   Private Placement with Aspire Capital In July 2018, we entered into a securities purchase agreement (the “ PIPE Agreement ”) with Aspire Capital for the sale of up to $2.0 million of shares of our common stock (or pre-funded warrants) and warrants, in two tranches. Upon the initial closing, we sold to Aspire Capital (i) a pre-funded warrant to purchase up to 2.5 million shares of our common stock with an exercise price of $0.01 per share (“ Pre-Funded Warrant ”) and (ii) a warrant to purchase up to 2.5 million shares of our common stock with an exercise price of $0.74 per share (a “ Warrant ”), for an aggregate purchase price of approximately $1.0 million. In addition, pursuant to the PIPE Agreement, in September 2018, we sold to Aspire Capital (i) a second Pre-Funded Warrant to purchase up to 2.5 million shares of common stock exercise price of $0.01 per share and (ii) a second Warrant to purchase an additional 2.5 million shares of common stock at an exercise price of $0.74 per share, for an additional aggregate purchase price of approximately $1.0 million. The aggregate proceeds from the sale of Pre-Funded Warrants and Warrants to Aspire Capital are $1.9 million after deduction of legal fees and registration costs of approximately $0.05 million. The Warrants and Pre-Funded Warrants expire five years after their respective issuance date and have substantially similar other terms , except (i) for exercise price and (ii) that the Warrants are exercisable on the date that is six months after issuance and the Pre-Funded Warrants are immediately exercisable after issuance. The shares underlying the Pre-Funded Warrants and Warrants are registered under a registration statement that became effective in September 2018 (Registration No.333-226738).  At Market Issuance Sales Agreements We filed a shelf registration statement on Form S-3 with the SEC in November 2016 (Registration No. 333-214598) for the offering of various securities, up to $15 million, over a period of up to three years. On December 30, 2016, we entered into an At Market Issuance Sales Agreement (“ ATM ”) with FBR Capital Markets & Co. (“ FBR ”) for the sale of up to $10 million in shares of our common stock under the shelf registration statement (the “ First ATM ”). From January through March 2017, we sold an aggregate of 4.1 million shares of our common stock at an average price of $2.46 per share under the First ATM for net proceeds of approximately $9.6 million, after deduction of approximately $0.4 million in FBR fees and commissions, legal fees and other offering costs.  On August 14, 2017, we entered into a new ATM agreement with FBR for the sale of up to approximately $4.4 million in shares of our common stock registered under the shelf registration statement (the “ Second ATM ”). From August to December 2017, we completed the sale of approximately 2.1 million shares of our common stock at an average price of $1.50 under the Second ATM for net proceeds of approximately $3.0 million, after deduction of approximately $0.2 million in FBR fees and commissions, legal fees and other offering costs. From March to May 2018, we completed the sale of approximately 1.4 million shares of our common stock at an average price of $0.87 per share under the Second ATM for aggregate net proceeds of approximately $1.1 million, after deduction of approximately $0.1 million in FBR fees and commissions. We had no additional amounts available under the shelf registration statement as of December 31, 2018.  Equity Line Agreement In October 2017, we entered into a common stock purchase agreement (the “ Equity Line Agreement ”) with Aspire Capital. Under the Equity Line Agreement, Aspire Capital committed to purchase up to an aggregate of $20 mil lion in shares of our common stock over the 30 -month term of the Equity Line Agreement. In consideration for entering into the Equity Line Agreement, we issued to Aspire Capital approximately 0.3 million shares of our common stock as a commitment fee. We filed a registration statement to register the sale of up to 4 million shares of our common stock by Aspire Capital under the Equity Line Agreement. The registration statement was declared effective November 27, 2017 (File No. 333-221250).  Under the Equity Line Agreement, on any trading day selected by us, we have the right, in our sole discretion, to present Aspire Capital with a purchase notice, directing Aspire Capital to purchase up to 0.15 million shares of our common stock, provided that the aggregate purchase amount for such shares does not exceed $0.5 million and subject to the maximum aggregate amount of $20 million. The per share purchase price for each purchase notice is equal to the lesser of (i) the lowest sale price of our common stock on the purchase date; or (ii) the arithmetic average of the three lowest closing sale prices for our common stock during the ten consecutive trading days ending on the trading day immediately preceding the purchase date. In addition, on any date on which we submit a purchase notice to Aspire Capital, we also have the right, in our sole discretion, to present Aspire Capital with a volume-weighted average price (“ VWAP ”) purchase notice directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of our common stock traded on its principal market on the next trading day, or such lesser amount as we may determine. The purchase price per share pursuant to the VWAP purchase notice is generally 97% of the volume-weighted average price for our common stock traded on its principal market on the VWAP purchase date, subject to terms and limitations of the agreement.  The number of shares that may be issued to Aspire Capital under the Equity Line Agreement was limited to that number of shares representing 19.99% of our pre-transaction shares outstanding (the “ Exchange Cap ”), unless shareholder approval was obtained or unless the average price for shares sold in excess of the Exchange Cap is equal or greater to $1.48 which represents the closing bid price of our common stock at the date we entered into the Equity Line Agreement. In June 2018, our shareholders approved the issuance of shares to Aspire Capital under the Equity Line Agreement in excess of 19.99% of our pre-transaction shares outstanding.  In 2017, we sold an aggregate of 0.77 million shares of our common stock to Aspire Capital under the Equity Line Agreement for aggregate net proceeds of approximately $0.96 million after deduction of legal and other offering costs of approximately $0.04 million. From January 2018 to June 2018, we sold an aggregate of 2.9 million shares of our common stock to Aspire Capital under the Equity Line Agreement for aggregate net proceeds of approximately $2.0 million. As of December 31, 2018, we had no registered shares available under the Equity Line Agreement. Upon registration of additional shares, and subject to the terms and conditions of the Equity Line Agreement, including a $0.50 per share minimum price, we have $16.9 million remaining under the Equity Line Agreement.  Director Stock Purchases On March 26, 2018, three of our directors purchased an aggregate of 0.2 million shares of our common stock in an unregistered sale of equity securities at a purchase price of $0.83 per share. In February 2017, one of our directors purchased 0.1 million shares of our common stock in an unregistered sale of equity securities at a purchase price of $2.11 per share. Director purchases of our common stock were made at or above market price at the date of purchase (see Note 14).  Stock for Services For the year ended December 31, 2017, we issued an aggregate of 0.3 million shares of unregistered common stock to two consultants in exchange for an aggregate of approximately $0.4 million in prepaid retainers for executive consulting and other advisory services. We have no registration obligation with respect to these shares.  Common Stock Warrants  In December 2018, we issued a warrant for the purchase of up to 5.0 million shares of our common stock at $0.16 per share to Brickell in connection with an amendment to the CPIA (see Note 7). The CPIA is recorded as a liability at its estimated fair value. At the transaction date, the estimated fair value of the liability to Brickell exceeded the net proceeds received from Brickell. Accordingly, no value was assigned to the warrants issued in connection with the transaction. The warrant is immediately exercisable, expire s five years from the date of issuance and include s cashless exercise and registration rights. Th e shares underlying the warrant have not yet been registered.  As of December 31, 2018, we had outstanding warrants for the purchase of up to 13.3 million shares of our common stock, including Pre-Funded Warrants for the purchase of up to 2.9 million shares of our common stock. The estimated grant date fair value of these warrants of $1.8 million and $0.8 million at December 31, 2018 and 2017, respectively, is included in shareholders’ deficit in our consolidated balance sheets. As of December 31, 2018, our outstanding warrants have an average exercise price of $0.39 per share and a weighted average remaining life of approximately five years.  For the year ended December 31, 2018, we issued approximately 2.0 million shares of our common stock upon cashless exercise of 2.1 million Pre-Funded Warrants. In addition, a warrant for the purchase of 0.07 million shares with an exercise price of $3.25 per share expired unexercised in 2018. There were no warrant exercises or expirations for the year ended December 31, 2017 and no cash received from warrant exercises for 2018 or 2017.  Shareholder Protection Rights Agreement On November 20, 2015, we amended our Shareholder Protection Rights Agreement (“ Rights Agreement ”) dated November 21, 2005. The amendment extends the expiration date of the Rights Agreement from November 21, 2015 to November 20, 2020 and decreases the exercise price of the rights to $14.50 after giving effect to the one -for-ten reverse stock split that became effective March 30, 2016.  The Rights Agreement provided for the issuance, on November 29, 2005, as a dividend, rights to acquire fractional shares of Series E Preferred Stock. We did not assign any value to the dividend as the value of these rights is not believed to be objectively determinable. The principal objective of the Rights Agreement is to cause someone interested in acquiring us to negotiate with our Board rather than launch an unsolicited or hostile bid. The Rights Agreement subjects a potential acquirer to substantial voting and economic dilution. Each share of common stock issued by ParkerVision will include an attached right.  The rights initially are not exercisable and trade with the common stock of ParkerVision. In the future, the rights may become exchangeable for shares of Series E Preferred Stock with various provisions that may discourage a takeover bid. Additionally, the rights have what are known as “flip-in” and “flip-over” provisions that could make any acquisition of us more costly to the potential acquirer. The rights may separate from the common stock following the acquisition of 15% or more of the outstanding shares of common stock by an acquiring person. Upon separation, the holder of the rights may exercise their right at an exercise price of $14.50 per right (the “ Exercise Price ”), subject to adjustment and payable in cash. Upon payment of the Exercise Price, the holder of the right will receive from us that number of shares of common stock having an aggregate market price equal to twice the Exercise Price, as adjusted. The Rights Agreement also has a flip over provision allowing the holder to purchase that number of shares of common/voting equity of a successor entity, if we are not the surviving corporation in a business combination, at an aggregate market price equal to twice the Exercise Price. We have the right to substitute for any of our shares of common stock that we are obligated to issue, shares of Series E Preferred Stock at a ratio of one ten-thousandth of a share of Series E Preferred Stock for each share of common stock. The Series E Preferred Stock, if and when issued, will have quarterly cumulative dividend rights payable when and as declared by the Board, liquidation, dissolution and winding up preferences, voting rights and will rank junior to other securities of ParkerVision unless otherwise determined by the Board.  The rights may be redeemed upon approval of the Board at a redemption price of $0.01 .

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2018
Share-Based Compensation [Abstract]
Share-Based Compensation	12. SHARE-BASED COMPENSATION  The following table presents share-based compensation expense included in our consolidated statements of comprehensive loss for the years ended December 31, 2018 and 2017, respectively (in thousands):     2018 2017  Research and development expense $ 169 $ 564  Selling, general, and administrative expense 831 1,600  Restructuring expense 50 -  Total share-based compensation expense $ 1,050 $ 2,164   We did not capitalize any expense related to share-based payments. As of December 31, 2018, there was $0.2 million of total unrecognized compensation cost related to all non-vested share-based compensation awards. That cost is expected to be recognized over a weighted-average period of approximately one year.  Stock Incentive Plans  2011 Long-Term Incentive Equity Plan We adopted a long-term incentive equity plan in September 2011 that, as amended in 2014, 2016 and 2017, provided for the grant of stock-based awards to employees, officers, directors and consultants, not to exceed 3.0 million shares of common stock (the “ 2011 Plan ”). The 2011 Plan provides for benefits in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, and other stock based awards. Forfeited and expired options under the 2011 Plan become available for reissuance. The plan provides that no participant may be granted awards in excess of 150,000 shares in any calendar year. At December 31, 2018, 296,952 shares of common stock were available for future grants under the 2011 Plan.  2008 Equity Incentive Plan We adopted an equity incentive plan in August 2008 (the “ 2008 Plan ”). The 2008 Plan provides for the grant of stock-based awards to employees (excluding named executives), directors and consultants, not to exceed 50,000 shares of common stock. The 2008 Plan provides for benefits in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, and other stock based awards. Forfeited and expired options under the 2008 Plan become available for reissuance. The plan provides that no participant may be granted awards in excess of 5,000 shares in any calendar year. At December 31, 2018, 19,673 shares of common stock were available for future grants under the 2008 Plan.  2000 Performance Equity Plan We adopted a performance equity plan in July 2000 (the “ 2000 Plan ”). The 2000 Plan provided for the grant of options and other stock awards to employees, directors and consultants, not to exceed 500,000 shares of common stock. The 2000 Plan provided for benefits in the form of incentive and nonqualified stock options, stock appreciation rights, restricted stock awards, stock bonuses and various stock benefits or cash. No additional awards may be granted under this plan.  Restricted Stock Awards RSAs are issued as executive and employee incentive compensation and as payment for services to others. The value of the award is based on the closing price of our common stock on the date of grant. RSAs are generally immediately vested.  Restricted Stock Units RSUs are issued as incentive compensation to executives, employees, and non-employee directors as well as payment for services to third parties. Each RSU represents a right to one share of our common stock, upon vesting. The RSUs are not entitled to voting rights or dividends, if any, until vested. RSUs generally vest over a one to three year period for employee awards, a one year period for non-employee director awards and the life of the related service contract for third-party awards. The fair value of RSUs is generally based on the closing price of our common stock on the date of grant and is amortized to share-based compensation expense over the estimated life of the award, generally the vesting period. In the case of RSUs issued to third parties, the fair value is recognized based on the closing price of our common stock on each vesting date.  RSAs and RSUs The following table presents a summary of RSA and RSU activity under the 2000, 2008, and 2011 Plans (collectively, the “ Stock Plans ”) as of December 31, 2018 (shares in thousands):      Non-vested Shares  Shares Weighted-Average Grant Date Fair Value  Non-vested at beginning of year 521 $ 1.98  Granted 221 0.37  Vested (629) 1.42  Forfeited (99) 1.94  Non-vested at end of year 14 $ 1.98   The total fair value of RSAs and RSUs vested under the Stock Plans for the year ended December 31, 2018 is $0.3 million.  Stock Options Stock options are issued as incentive compensation to executives, employees, non-employee directors, and third parties. Stock options are generally granted with exercise prices at or above fair market value of the underlying shares at the date of grant. The fair value of options granted is estimated using the Black-Scholes option pricing model. Generally, fair value is determined as of the grant date. In the case of option grants to third parties, the fair value is estimated at each interim reporting date until vested. Options for employees, including executives and non-employee directors, are generally granted under the Stock Plans.  The following table presents a summary of option activity under the Stock Plans for the year ended December 31, 2018 (shares in thousands):     Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value ($)  Outstanding at beginning of year 1,007 $ 10.82  Granted 507 0.60  Exercised - -  Forfeited (42) 1.59  Expired (244) 9.96  Outstanding at end of year 1,228 7.09 4.66 years $ -  Vested and expected to vest at end of year 849 $ 9.98 3.73 years $ -   The weighted average per share fair value of option shares granted during the years ended December 31, 2018 and 2017 was $0.46 and $1.52 , respectively. The total fair value of option shares vested was $0.5 million and $0.2 million for the years ended December 31, 2018 and 2017, respectively.  The fair value of option grants under the Stock Plans for the years ended December 31, 2018 and 2017, respectively, was estimated using the Black-Scholes option-pricing model with the following assumptions:     Year ended December 31,  2018 2017  Expected option term 1 5 to 6 years 4 to 6 years  Expected volatility factor 2 68.8% to 93.6% 98.0% to 100.8%  Risk-free interest rate 3 2.6% to 3.0% 1.7% to 2.2%  Expected annual dividend yield 0% 0%  1 The expected term was generally determined based on historical activity for grants with similar terms and for similar groups of employees and represents the period of time that options are expected to be outstanding. For employee options, groups of employees with similar historical exercise behavior are considered separately for valuation purposes. For consultants, the expected term was determined based on the contractual life of the award. 2 The stock volatility for each grant is measured using the weighted average of historical daily price changes of our common stock over the most recent period equal to the expected option life of the grant. 3 The risk-free interest rate for periods equal to the expected term of the share option is based on the U.S. Treasury yield curve in effect at the measurement date.  Options by Price Range The options outstanding at December 31, 2018 under all plans have exercise price ranges, weighted average contractual lives, and weighted average exercise prices are as follows (weighted average lives in years and shares in thousands):     Options Outstanding Options Vested  Range of Exercise Prices Number Outstanding at December 31, 2018 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life Number Exercisable at December 31, 2018 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life  $0.60 - $1.23 502 $ 0.60 6.71 127 $ 0.61 6.65  $1.80 - $13.20 459 2.43 4.65 455 2.43 4.64  $13.80 - $22.60 28 14.05 2.48 28 14.05 2.48  $23.80 - $38.80 230 28.25 0.55 230 28.25 0.55  $45.10 - $45.10 9 45.10 1.96 9 45.10 1.96  1,228 $ 7.09 4.66 849 $ 9.98 3.73   Upon exercise of options under all plans, we issue new shares of our common stock. For shares issued upon exercise of equity awards granted under the Stock Plans, the shares of common stock are registered. For shares issued upon exercise of non-plan awards, the shares are not registered unless they have been subsequently registered by us on a registration statement. We had no option exercises for the years ended December 31, 2018 or 2017 .

Restructuring Charges

Restructuring Charges	12 Months Ended
	Dec. 31, 2018
Restructuring Charges [Abstract]
Restructuring Charges	13. RESTRUCTURING CHARGES  In August 2018, as a result of our limited capital resources, our Board approved plans to reduce our ongoing operating expenses, including a reduction in workforce of approximately 30 employees and closure of our engineering design facility in Lake Mary, Florida. As a result of the cost reduction measures, we ceased any ongoing integrated circuit design activities and significantly reduced our sales and marketing expenditures with respect to our Milo products. Expenses related to our restructuring are included in operating expenses in our consolidated statements of comprehensive loss under the heading “Restructuring charges.”  Restructuring charges for the year ended December 31, 2018 include the following (in thousands):     2018  One-time termination benefits $ 135  Lease expense 163  Asset impairment charges 375  Other 17  $ 690   Termination Benefits Accrued one-time termination benefits consist of the following (in thousands):     2018  Accrued termination benefits, beginning of period $ -  Termination benefits recognized 135  Termination benefits settled (115)  Accrued termination benefits, end of period $ 20   Lease Payable In connection with the cease-use date of our Lake Mary, Florida facility, we recorded a lease payable for the estimated fair value of remaining lease rental payments, less estimated sublease rentals, net of deferred rent. Our lease payable consists of the following (in thousands):     2018  Lease payable, beginning of period $ -  Present value of future minimum lease payments less estimated future sublease rentals, net of deferred rent of $62 182  Settlements (48)  Change in estimate 43  Lease payable, end of period 177  Current portion of lease payable 86  Long-term portion of lease payable $ 91  

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	14. RELATED PARTY TRANSACTIONS  We paid approximately $0.03 million and $0.03 million in 2018 and 2017, respectively, for patent-related legal services to SKGF , of which Robert Sterne, one of our directors since September 2006, is a partner. In addition, we paid approximately $0.06 million a nd $0.07 million in 2018 and 2017, respectively for principal and interest on an unsecured note payable to SKGF (the “ SGKF Note ”). The SKGF Note was issued in 2016, to convert outstanding unpaid fees to an unsecured promissory note. The SKGF Note was amended in January 2018 and August 2018 to defer principal payments. The SKGF Note allows for interest at 8% per annum and matures on March 31, 2020 . At December 31, 2018, the outstanding balance of the note, including accrued and unpaid interest is approximately $0.8 million (see Note 7).  On September 10, 2018, we sold an aggregate of $0.4 million in promissory notes, convertible into shares of our common stock at a fixed conversion price of $0.40 to related parties on the same terms as other convertible notes sold in the same transaction (see Note 7). Jeffrey Parker , our chief executive officer and chairman of the Board, Paul Rosenbaum , one of our directors since December 2016, and incoming independent director, Lewis Titterton, each purchased a convertible note with a face value of $0.1 million. In addition, Stacie Wilf, sister to Jeffrey Parker, purchased a convertible note with a face value of $0.1 million. On March 26, 2018 , three of our directors purchased an aggregate of 0.2 million shares of our common stock in an unregistered sale of equity securities at a purchase price of $0.83 per share, which represented the closing bid price of our common stock on the purchase date. In February 2017, one of our directors, Mr. Paul Rosenbaum, purchased approximately 0.1 million shares of our common stock in an unregistered sale of equity securities at a purchase price of $2.11 per share (see Note 11).

Concentrations Of Credit Risk

Concentrations Of Credit Risk	12 Months Ended
	Dec. 31, 2018
Concentrations Of Credit Risk [Abstract]
Concentration Of Credit Risk	 15. CONCENTRATIONS OF CREDIT RISK  Financial instruments that potentially subject us to a concentration of credit risk principally consist of cash and cash equivalents, restricted cash equivalents, and our available for sale securities. Cash and cash equivalents are primarily held in bank accounts and overnight investments. At times our cash balances on deposit with banks may exceed the balance insured by the F.D.I.C. Restricted cash equivalents are held in accounts with brokerage institutions and consist of short-term money market funds. Our available-for-sale securities are held in accounts with brokerage institutions and consist of mutual funds invested primarily in short-term municipal securities.  We maintain our investments with what management believes to be quality financial institutions and while we limit the amount of credit exposure to any one institution, we could be subject to credit risks from concentration of investments in a single fund as well as credit risks arising from adverse conditions in the financial markets as a whole.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	 16. SUBSEQUENT EVENTS  In February and March 2019, we sold an aggregate of $1.3 million in convertible notes to accredited investors. The notes mature five years from the date of issuance and are convertible, at the holders’ option, into shares of our common stock at a fixed conversion price of $0.25 per share. The notes bear interest at a stated rate of 8% per annum. Interest is payable quarterly, and we may elect, subject to certain equity conditions, to pay interest in cash, shares of our common stock, or a combination thereof.  On March 29, 2019, we amended our promissory note payable to SKGF to provide for a decrease in the interest rate from 8% to 4% per year, an extension of the maturity date from March 2020 to April 2022 , and a reduction in the monthly payment. In connection with this amendment, SKGF also waived any prior payment defaults under the note. As a result of this amendment, approximately $0.65 million of our obligation to SKGF was reclassified from current to long-term liabilities as of December 31, 2018. 

Significant Accounting Polici_2

Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2018
Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Certain reclassifications have been made to prior period amounts to conform to the current period presentation. The consolidated financial statements include the accounts of ParkerVision, Inc. and our wholly-owned German subsidiary, ParkerVision GmbH , after elimination of all intercompany transactions and accounts.
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The more significant estimates made by us include projected future cash flows and risk-adjusted discount rates for estimating the fair value of our secured contingent payment obligation, the volatility and estimated lives of share-based awards used in the estimate of the fair market value of share-based compensation, the assessment of recoverability of long-lived assets, the amortization periods for intangible and long-lived assets, and the valuation allowance for deferred taxes. Actual results could differ from the estimates made. We periodically evaluate estimates used in the preparation of the financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation.
Cash, Cash Equivalents, and Restricted Cash Equivalents	Cash, Cash Equivalents, and Restricted Cash Equivalents We consider cash and cash equivalents to include cash on hand, interest-bearing deposits, overnight repurchase agreements and investments with original maturities of three months or less when purchased. Restricted cash equivalents represent money market investments that are restricted for specific use in payment of legal fees and expenses related to certain of our patent infringement actions. The restricted money market investments have weighted average maturities of three months or less when purchased and are recorded at fair value. We have determined that the fair value of our restricted money market investments fall within Level 1 in the fair value hierarchy (see Note 8). 
Inventory	Inventory Inventory is stated at the lower of actual cost, as determined under the first-in, first-out method, or estimated net realizable value. We review our inventory for estimated obsolescence or unmarketable inventory and write down inventory for the difference between cost and estimated market value based upon assumptions about future demand. Future demand is affected by market conditions, technological obsolescence, new products and strategic plans, each of which is subject to change. 
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined using the straight-line method over the following estimated useful lives:      Manufacturing and office equipment 5 -7 years  Leasehold improvements Shorter of useful life or remaining life of lease  Furniture and fixtures 7 years  Computer equipment and software 3 -5 years  The cost and accumulated depreciation of assets sold or retired are removed from their respective accounts, and any resulting net gain or loss is recognized in the accompanying consolidated statements of comprehensive loss. The carrying value of long-lived assets is reviewed on a regular basis for the existence of facts, both internally and externally, that may suggest impairment. Recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the assets exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the assets.
Intangible Assets	Intangible Assets Patents, copyrights and other intangible assets are amortized using the straight-line method over their estimated period of benefit. We estimate the economic lives of our patents and copyrights to be fifteen to twenty years. We estimate the economic lives of other intangible assets, including licenses, based on estimated technological obsolescence, to be two to five years, which is generally shorter than the contractual lives. Management evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that may warrant revised estimates of useful lives or that may indicate impairment exists.
Secured Contingent Payment Obligation	Secured Contingent Payment Obligation We have accounted for our secured contingent repayment obligation as long-term debt in accordance with Accounting Standards Codification (“ ASC ”) 470-10-25, “Sales of Future Revenues or Various other Measures of Income.” Our repayment obligations are contingent upon the receipt of proceeds from patent enforcement and/or patent monetization actions. We have elected to measure our secured contingent payment obligation at its fair value in accordance with ASC 825, “Financial Instruments” based on the variable and contingent nature of the repayment provisions. We have determined that the fair value of our secured contingent payment obligation falls within Level 3 in the fair value hierarchy which involves significant estimates and assumptions including projected future patent-related proceeds and the risk-adjusted rate for discounting future cash flows (see Note 8). Actual results could differ from the estimates made. Changes in fair value, including the component related to imputed interest, are included in the accompanying consolidated statements of comprehensive loss under the heading “Change in fair value of contingent payment obligation”.
Leases	Leases Our facilities are leased under operating leases. For those leases that contain rent escalations or rent concessions, we record the total rent payable during the lease term on a straight-line basis over the term of the lease with the difference between the rents paid and the straight-line rent recorded as a deferred rent liability in the accompanying consolidated balance sheets.  In February 2016, the FASB established ASC 842, “Leases” by issuing ASU 2016-02 to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. ASC 842 was subsequently amended by ASU 2018-01, ASU 2018-10 and ASU 2018-11 which provided practical expedients for adoption of ASC 842. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. ASC 842 is effective for interim and annual periods beginning after December 15, 2018. A modified retrospective transition approach is required for adoption, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either the effective date or the beginning of the earliest comparative period presented in the financial statements as its date of initial application.  ASC 842 will be effective for us as of January 1, 2019, and we have elected to use the effective date as the initial application date. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and period prior to January 1, 2019. The new standard provides a number of practical expedients in transition and we expect to elect the package of practical expedients which permits us not to reassess under the new standard our prior conclusions about lease identification, lease classification and treatment of initial direct costs. We expect the adoption of this new standard to result in the recognition of operating lease right-to-use assets and operating lease liabilities of approximately $0.56 million and $0.61 million, respectively, primarily related to our facilities leases. In addition, adoption of the new standard will result in significant new disclosures about our leasing activities.
Revenue Recognition	Revenue Recognition As of January 1, 2018, we adopted ASC 606, “Revenue from Contracts with Customers” which implements a common revenue standard that clarifies the principles for recognizing revenue. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The adoption of ASC 606 had no material effect on our consolidated financial statements .  We derive revenue from licensing of our intellectual property, settlements from patent infringement disputes and sales of products. The timing of revenue recognition and the amount of revenue recognized depends upon a variety of factors, including the specific terms of each arrangement and the nature of our deliverables and obligations. In general, we recognize revenue when the performance obligations to our customers have been met. For the sale of products, the performance obligation is generally met at the time product is delivered to the customer. Estimated product returns are deducted from revenue and recorded as a liability. Revenue from the sale of our products includes shipping and handling charged to the customer. Product revenue is recorded net of sales tax collected from customers, discounts, and actual and estimated future returns.  The consideration received from patent license and settlement agreements is allocated to the various elements of the arrangement to the extent the revenue recognition differs between the elements of the arrangement. Elements related to past and future royalties as well as elements related to settlement will be recorded as revenue in our consolidated statements of comprehensive loss when our performance obligations related to each element have been met.
Shipping and Handling Costs	  Shipping and Handling Costs Shipping and handling costs related to product sales for the years ended December 31, 2018 and 2017 were approximately $12,000 and $5,000 , respectively. These costs are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.
Advertising Expense	Advertising Expense Advertising costs are expensed as incurred. Advertising expenses of approximately $0.7 million and $0.4 million for the years ended December 31, 2018 and 2017, respectively, are included in selling, general, and administrative expenses in the accompanying consolidated statements of comprehensive loss.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred and include salaries and benefits, costs paid to third party contractors, prototype expenses, an allocated portion of facilities costs, maintenance costs for software development tools, and depreciation.
Accounting for Share-Based Compensation	Accounting for Share-Based Compensation We have various share-based compensation programs which provide for equity awards including stock options, restricted stock units (“ RSUs ”) and restricted stock awards (“ RSAs ”). We calculate the fair value of employee share-based equity awards on the date of grant and recognize the calculated fair value as compensation expense over the requisite service periods of the related awards. We estimate the fair value of stock option awards using the Black-Scholes option valuation model. This valuation model requires the use of highly subjective assumptions and estimates including how long employees will retain their stock options before exercising them and the volatility of our common stock price over the expected life of the equity award. Such estimates, and the basis for our conclusions regarding such estimates, are outlined in detail in Note 12. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards. We account for forfeitures of share-based awards as they occur.  As of January 1, 2018, we adopted ASU No. 2017-09, “Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.” This update provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. The adoption of this guidance did not have a material effect on our consolidated financial statements.
Income Taxes	Income Taxes The provision for income taxes is based on loss before taxes as reported in the accompanying consolidated statements of comprehensive loss. Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when, based on available objective evidence, it is more likely than not that the benefit of such assets will not be realized. Our deferred tax assets exclude unrecognized tax benefits which do not meet a more-likely-than-not threshold for financial statement recognition for tax positions taken or expected to be taken in a tax return.  On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “ Tax Act ”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease to 21% effective for tax years beginning after December 31, 2017.
Loss per Common Share	Loss per Common Share Basic loss per common share is determined based on the weighted-average number of common shares outstanding during each year. Diluted loss per common share is the same as basic loss per common share as all potential common shares are excluded from the calculation, as their effect is anti-dilutive.  The number of shares underlying outstanding options, warrants, unvested RSUS and convertible notes at December 31, 2018 and 2017 were as follows (in thousands):     2018 2017  Options outstanding 1,228 1,007  Warrants outstanding 13,279 420  Unvested RSUs 14 521  Shares underlying convertible notes 2,746 -  17,267 1,948   These potential shares were excluded from the computation of diluted loss per share as their effect would have been anti-dilutive.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Significant Accounting Policies [Abstract]
Schedule Of Property And Equipment Useful Lives	   Manufacturing and office equipment 5 -7 years  Leasehold improvements Shorter of useful life or remaining life of lease  Furniture and fixtures 7 years  Computer equipment and software 3 -5 years 
Summary Of Anti-Dilutive Shares	   2018 2017  Options outstanding 1,228 1,007  Warrants outstanding 13,279 420  Unvested RSUs 14 521  Shares underlying convertible notes 2,746 -  17,267 1,948  

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2018
Inventories [Abstract]
Schedule Of Inventories	   2018 2017  Raw materials $ 139 $ 573  Work-in-process - -  Finished goods 941 452  1,080 1,025  Inventory reserves (982) -  98 1,025  
Schedule Of Inventory Reserves	   2018 2017  Inventory reserves at beginning of year $ - $ -  Impairment charges 1,134 125  Write down of impaired inventories (152) (125)  Inventory reserves at end of year $ 982 $ -  

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
Prepaid Expenses [Abstract]
Schedule Of Prepaid Expenses	   2018 2017  Prepaid services $ 252 $ 253  Prepaid bonds for German statutory costs 199 62  Prepaid licenses, software tools and support 51 404  Prepaid inventory and production tooling - 121  Prepaid advertising - 75  Prepaid insurance 19 54  Other prepaid expenses 17 33  $ 538 $ 1,002  

Property And Equipment, Net (Ta

Property And Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Property And Equipment, Net [Abstract]
Schedule Of Property And Equipment, Net	   2018 2017  Equipment and software, including equipment purchased under capital leases of $17 and $297 at December 31, 2018 and 2017, respectively $ 1,555 $ 6,556  Leasehold improvements 786 786  Furniture and fixtures 182 185  2,523 7,527  Less accumulated depreciation, including accumulated depreciation for equipment purchased under capital leases of $13 and $206 at December 31, 2018 and 2017, respectively (2,394) (7,151)  $ 129 $ 376  

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Intangible Assets [Abstract]
Schedule Of Intangible Assets	   2018 2017   Patents and copyrights $ 18,350 $ 19,324  Less accumulated amortization (14,448) (14,248)  $ 3,902 $ 5,076  
Schedule Of Future Amortization Expense	   2019 $ 713  2020 520  2021 448  2022 406  2023 359  2024 and thereafter 1,456  Total $ 3,902  

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2018
Debt [Abstract]
Schedule Of Notes Payable	    Description 2018 2017  Note payable to a related party $ 836 $ 825  Secured note payable 2,400 -  Total notes payable 3,236 825  Less current maturities 2,437 294  Long-term note payable $ 799 $ 531  
Summary Of Aggregate Maturities	   2019 $ 2,437  2020 90  2021 93  2022 616  Total $ 3,236  
Schedule Of Convertible Notes Payable	   Description Fixed Conversion Rate Effective Interest Rate Maturity Date 2018  Convertible notes dated September 10, 2018 $0.40 8.3% September 7, 2023 $ 800  Convertible notes dated September 19, 2018 $0.57 8.3% September 19, 2023 425  Total principal balance 1,225  Less unamortized discount 388  $ 837  
Reconciliation Of Secured Contingent Obligation At Fair Value	      2018 2017  Secured contingent payment obligation, beginning of year $ 15,896 $ 14,185  Proceeds from contingent payment obligation 4,000 1,000  Repayment - -  Change in fair value 5,661 711  Secured contingent payment obligation, end of year $ 25,557 $ 15,896  

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Measurements [Abstract]
Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis	   Fair Value Measurements  Total Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)  December 31, 2018:  Liabilities:  Secured contingent payment obligation $ 25,557 $ - $ - $ 25,557    December 31, 2017:  Assets:  Available-for-sale securities $ 26 $ 26 $ - $ -  Restricted cash equivalents 1,000 1,000 - -  Liabilities:  Secured contingent payment obligation 15,896 - - 15,896  

Income Taxes And Tax Status (Ta

Income Taxes And Tax Status (Tables)	12 Months Ended
	Dec. 31, 2018
Income Taxes And Tax Status [Abstract]
Schedule Of Effective Income Tax Rate Reconciliation	   2018 2017  Tax benefit at statutory rate $ (4,382) $ (6,548)  State tax benefit (897) (674)  Impact of the Tax Act - 41,646  Increase (decrease) in valuation allowance 5,304 (34,346)  Research and development credit (51) (129)  Other 26 51  $ - $ -  
Schedule Of Deferred Tax Assets And Liabilities	   2018 2017  Gross deferred tax assets:  Net operating loss carry-forward $ 84,192 $ 82,168  Research and development credit 7,879 8,051  Stock compensation 1,027 1,248  Patents and other 1,495 1,427  Contingent payment obligation 2,842 1,409  Inventories 249 -  Fixed assets 25 25  Accrued liabilities 146 49  Deferred rent and lease liabilities 46 20  Charitable contributions 5 7  Deferred revenue - 5  Capital loss carry-forward 3 3  Warranty reserve 4 2  Bad debt expense - 1  97,913 94,415  Less valuation allowance (97,816) (94,415)  97 -  Gross deferred tax liabilities:  Convertible debt (97) -  (97) -  Net deferred tax asset $ - $ -  
Schedule Of Unrecognized Tax Benefits Roll Forward	   2018 2017  Unrecognized tax benefits – beginning of year $ 927 $ 1,370  Impact of the Tax Act - (443)  Unrecognized tax benefits – end of year $ 927 $ 927  

Commitments And Contingencies (

Commitments And Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments And Contingencies [Abstract]
Summary Of Facilities Under Lease Agreements	   Description Lease Start Date Lease End Date Renewal options remaining Straight line monthly rental payment (in thousands)  Corporate office, Jacksonville, Florida 7/15/2018 7/31/2019 none $ 31  Wireless design facility, Lake Mary, Florida 7/1/2017 11/30/2022 2 options to extend for 36 months each $ 13  Warehouse and production facility, Jacksonville, Florida 7/1/2017 7/31/2020 none $ 2  
Schedule Of Future Minimum Lease Payments For Capital Leases And Operating Leases	   Contractual obligations: 2019 2020 2021 and thereafter Total  Operating leases $ 372 $ 191 $ 345 $ 908  Capital leases $ 2 $ 1 $ - $ 3  

Stock Authorization And Issua_2

Stock Authorization And Issuance (Tables)	12 Months Ended
	Dec. 31, 2018
Stock Authorization And Issuance [Abstract]
Summary Of Equity Offerings	   Date Transaction # of Common Shares/ Units Sold Average Price per Share/Unit # of Warrants Issued (in 000’s) Average Exercise Price per Warrant Net Proceeds (1)  July 2018 and September 2018 Offerings under PIPE Agreement - - 10,000 $0.38 $ 1,901  March 2018 Director Stock Purchase 217 $0.83 - - $ 180  March - May 2018 Offerings under ATM 1,359 $0.87 - - $ 1,148  January - June 2018 Offerings under Equity Line Agreement 2,940 $0.70 - - $ 2,047  October - December 2017 Offerings under Equity Line Agreement 773 $1.29 - - $ 958  August - December 2017 Offerings under ATM 2,119 $1.50 - - $ 2,970  February 2017 Director Stock Purchase 81 $2.11 - - $ 170  January - March 2017 Offerings under ATM 4,072 $2.46 - - $ 9,581  (1) After deduction of applicable underwriters’ discounts, placement agent fees, and other offering costs.

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule Of Share-Based Compensation Expense Included In Statements Of Operations	   2018 2017  Research and development expense $ 169 $ 564  Selling, general, and administrative expense 831 1,600  Restructuring expense 50 -  Total share-based compensation expense $ 1,050 $ 2,164  
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary Of Options Activity	   Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value ($)  Outstanding at beginning of year 1,007 $ 10.82  Granted 507 0.60  Exercised - -  Forfeited (42) 1.59  Expired (244) 9.96  Outstanding at end of year 1,228 7.09 4.66 years $ -  Vested and expected to vest at end of year 849 $ 9.98 3.73 years $ -  
Summary Of Valuation Assumptions	    Year ended December 31,  2018 2017  Expected option term 1 5 to 6 years 4 to 6 years  Expected volatility factor 2 68.8% to 93.6% 98.0% to 100.8%  Risk-free interest rate 3 2.6% to 3.0% 1.7% to 2.2%  Expected annual dividend yield 0% 0%  1 The expected term was generally determined based on historical activity for grants with similar terms and for similar groups of employees and represents the period of time that options are expected to be outstanding. For employee options, groups of employees with similar historical exercise behavior are considered separately for valuation purposes. For consultants, the expected term was determined based on the contractual life of the award. 2 The stock volatility for each grant is measured using the weighted average of historical daily price changes of our common stock over the most recent period equal to the expected option life of the grant. 3 The risk-free interest rate for periods equal to the expected term of the share option is based on the U.S. Treasury yield curve in effect at the measurement date.
Summary Of Options And Warrants By Exercise Price Range	   Options Outstanding Options Vested  Range of Exercise Prices Number Outstanding at December 31, 2018 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life Number Exercisable at December 31, 2018 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life  $0.60 - $1.23 502 $ 0.60 6.71 127 $ 0.61 6.65  $1.80 - $13.20 459 2.43 4.65 455 2.43 4.64  $13.80 - $22.60 28 14.05 2.48 28 14.05 2.48  $23.80 - $38.80 230 28.25 0.55 230 28.25 0.55  $45.10 - $45.10 9 45.10 1.96 9 45.10 1.96  1,228 $ 7.09 4.66 849 $ 9.98 3.73  
Restricted Stock Award And Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary Of Restricted Stock Activity	   Non-vested Shares  Shares Weighted-Average Grant Date Fair Value  Non-vested at beginning of year 521 $ 1.98  Granted 221 0.37  Vested (629) 1.42  Forfeited (99) 1.94  Non-vested at end of year 14 $ 1.98  

Restructuring Charges (Tables)

Restructuring Charges (Tables)	12 Months Ended
	Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]
Schedule Of Restructuring Charges	   2018  One-time termination benefits $ 135  Lease expense 163  Asset impairment charges 375  Other 17  $ 690  
One-time Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Schedule Of Accrued Reserve	   2018  Accrued termination benefits, beginning of period $ -  Termination benefits recognized 135  Termination benefits settled (115)  Accrued termination benefits, end of period $ 20  
Lease Payable [Member]
Restructuring Cost and Reserve [Line Items]
Schedule Of Accrued Reserve	   2018  Lease payable, beginning of period $ -  Present value of future minimum lease payments less estimated future sublease rentals, net of deferred rent of $62 182  Settlements (48)  Change in estimate 43  Lease payable, end of period 177  Current portion of lease payable 86  Long-term portion of lease payable $ 91  

Significant Accounting Polici_4

Significant Accounting Policies (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018USD ($)segment	Dec. 31, 2017USD ($)
Significant Accounting Policies [Line Items]
Operating segments | segment	1
Reportable segments | segment	1
Shipping and handling costs	$ 12,000	$ 5,000
Advertising expenses	$ 700,000	$ 400,000
Corporate tax rate	21.00%	34.00%
Accounting Standards Update 2016-02 [Member]
Significant Accounting Policies [Line Items]
Operating lease asset	$ 560,000
Operating lease liability	$ 610,000
Patents And Copyrights [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Intangible assets, useful life	15 years
Patents And Copyrights [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Intangible assets, useful life	20 years
Licenses [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Intangible assets, useful life	2 years
Licenses [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Intangible assets, useful life	5 years

Significant Accounting Polici_5

Significant Accounting Policies (Schedule Of Property And Equipment Useful Lives) (Details)	12 Months Ended
	Dec. 31, 2018
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful life	Shorter of useful life or remaining life of lease
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful life	7 years
Minimum [Member] | Manufacturing And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful life	5 years
Minimum [Member] | Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Useful life	3 years
Maximum [Member] | Manufacturing And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful life	7 years
Maximum [Member] | Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Useful life	5 years

Significant Accounting Polici_6

Significant Accounting Policies (Summary Of Anti-Dilutive Shares) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares	17,267	1,948
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares	1,228	1,007
Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares	13,279	420
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares	14	521
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares	2,746

Liquidity And Going Concern (De

Liquidity And Going Concern (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Liquidity And Working Capital [Line Items]
Net loss		$ (20,869)	$ (19,259)
Net cash used in operating activities		(10,297)	(14,060)
Accumulated deficit		(392,292)	(371,423)
Net working capital		2,100
Cash, cash equivalents and available for sale securities		1,500
Net proceeds from debt financings		5,294	$ 1,000
Debt obligations due in 2019		$ 2,400
Subsequent Event [Member]
Liquidity And Working Capital [Line Items]
Net proceeds from debt financings	$ 1,300

Inventories (Schedule Of Invent

Inventories (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Inventories [Abstract]
Raw materials	$ 139	$ 573
Work-in-process
Finished goods	941	452
Inventory	1,080	1,025
Inventory reserves	(982)
Total inventories	$ 98	$ 1,025

Inventories (Schedule Of Inve_2

Inventories (Schedule Of Inventory Reserves) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Inventories [Abstract]
Inventory reserves at beginning of year
Impairment charges	1,134	125
Write down of impaired inventories	(152)	(125)
Inventory reserves at end of year	$ 982

Prepaid Expenses (Narrative) (D

Prepaid Expenses (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Prepaid Expenses [Abstract]
Impairment charges	$ 375

Prepaid Expenses (Schedule Of P

Prepaid Expenses (Schedule Of Prepaid Expenses) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Prepaid Expenses [Abstract]
Prepaid services	$ 252	$ 253
Prepaid bonds for German statutory costs	199	62
Prepaid licenses, software tools and support	51	404
Prepaid inventory and production tooling		121
Prepaid advertising		75
Prepaid Insurance	19	54
Other prepaid expenses	17	33
Prepaid expenses	$ 538	$ 1,002

Property And Equipment, Net (Na

Property And Equipment, Net (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Assets held for sale	$ 70
Estimated sale completion	12 months
Gain on sale of assets held for sale	$ 10
Property And Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense	130	$ 150
Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 2	$ 50
Minimum [Member]
Property, Plant and Equipment [Line Items]
Capital lease term	1 year
Maximum [Member]
Property, Plant and Equipment [Line Items]
Capital lease term	3 years

Property And Equipment, Net (Sc

Property And Equipment, Net (Schedule Of Property And Equipment, Net) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property and equipment	$ 2,523	$ 7,527
Less accumulated depreciation, including accumulated depreciation for equipment purchased under capital leases of $13 and $206 at December 31, 2018 and 2017, respectively	(2,394)	(7,151)
Property, Plant and Equipment, Net, Total	129	376
Capital leases	17	297
Accumulated depreciation for capital leases	13	206
Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	1,555	6,556
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	786	786
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 182	$ 185

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Intangible Assets [Abstract]
Amortization expense	$ 1.1	$ 1.2
Impairment of intangible assets	$ 0.1	$ 0.1

Intangible Assets (Schedule Of

Intangible Assets (Schedule Of Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Intangible Assets [Abstract]
Patents and copyrights	$ 18,350	$ 19,324
Less accumulated amortization	(14,448)	(14,248)
Intangible assets	$ 3,902	$ 5,076

Intangible Assets (Schedule O_2

Intangible Assets (Schedule Of Future Amortization Expense) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Intangible Assets [Abstract]
2019	$ 713
2020	520
2021	448
2022	406
2023	359
2024 and thereafter	1,456
Intangible assets	$ 3,902	$ 5,076

Debt (Narrative) (Details)

Debt (Narrative) (Details)	Mar. 29, 2019	Dec. 31, 2018USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)item$ / sharesshares	Dec. 31, 2017USD ($)	Dec. 31, 2018USD ($)$ / sharesshares	Sep. 10, 2018USD ($)
Debt Instrument [Line Items]
Repayments of Debt
Fair value of note payable		$ 3,000,000			3,000,000		$ 3,000,000
Proceeds from debt					$ 4,000,000	1,000,000
Exercise price per warrant | $ / shares		$ 0.39			$ 0.39		$ 0.39
Brickell [Member]
Debt Instrument [Line Items]
Shares converted, warrant | shares		5,000,000			5,000,000		5,000,000
Fair value of warrants		$ 0			$ 0		$ 0
Exercise price per warrant | $ / shares		$ 0.16			$ 0.16		$ 0.16
Secured Debt [Member]
Debt Instrument [Line Items]
Repayments of Debt							$ 3,300,000
Percentage of proceeds payment					100.00%
Proceeds from debt		$ 2,500,000			$ 4,000,000	$ 1,000,000	18,000,000
Fair value of payment obligation		$ 2,500,000			2,500,000		$ 2,500,000
Excess of fair value					$ 800,000
Promissory Notes [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Interest rate		12.00%			12.00%		12.00%
Debt payment per month					$ 200,000
Repayments of Debt					$ 100,000
Number of patents | item					25
Transfer of capital stock					6.00%
Percentage of proceeds payment					50.00%
Promissory Notes [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Interest rate		8.00%			8.00%		8.00%
Term					5 years
Proceeds from debt			$ 1,300,000
Beneficial conversion feature			400,000
Interest expense					$ 50,000
Amortization					20,000
Contractual interest					$ 30,000
Amortization period					4 years 9 months
Outstanding principal converted					$ 100,000
Shares issued | shares					250,000
Fixed Conversion Rate					0.40%
Aggregate common stock | item					2,700,000
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Measurement input		0.25			0.25		0.25
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Measurement input		0.20			0.20		0.20
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period Three [Member]
Debt Instrument [Line Items]
Measurement input		0.15			0.15		0.15
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period Four [Member]
Debt Instrument [Line Items]
Measurement input		0.10			0.10		0.10
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Default Rate [Member]
Debt Instrument [Line Items]
Measurement input		0.12			0.12		0.12
Promissory Notes [Member] | Convertible Debt [Member] | Related Parties [Member]
Debt Instrument [Line Items]
Debt								$ 400,000
Proceeds from debt			$ 400,000
Subsequent Event [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Interest rate				8.00%
Term				5 years
Proceeds from debt				$ 1,300,000
Sterne, Kessler, Goldstein & Fox, PLLC [Member] | Promissory Notes [Member] | Unsecured Note [Member]
Debt Instrument [Line Items]
Debt		$ 800,000			$ 800,000		$ 800,000
Interest rate		8.00%			8.00%		8.00%
Maturity date					Mar. 31, 2020
Sterne, Kessler, Goldstein & Fox, PLLC [Member] | Modifed Promissory Notes [Member] | Unsecured Note [Member]
Debt Instrument [Line Items]
Interest rate		12.00%			12.00%		12.00%
Debt payment per month					$ 48,500
Sterne, Kessler, Goldstein & Fox, PLLC [Member] | Subsequent Event [Member] | Promissory Notes [Member] | Unsecured Note [Member]
Debt Instrument [Line Items]
Interest rate	8.00%
Maturity date	Mar. 31, 2020
Sterne, Kessler, Goldstein & Fox, PLLC [Member] | Subsequent Event [Member] | Promissory Notes [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Interest rate	8.00%
Maturity date	Mar. 31, 2020
Sterne, Kessler, Goldstein & Fox, PLLC [Member] | Subsequent Event [Member] | Amended Promissory Note [Member] | Unsecured Note [Member]
Debt Instrument [Line Items]
Interest rate	4.00%
Maturity date	Apr. 30, 2022
Sterne, Kessler, Goldstein & Fox, PLLC [Member] | Subsequent Event [Member] | Amended Promissory Note [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Interest rate	4.00%
Maturity date	Apr. 30, 2022

Debt (Schedule Of Notes Payable

Debt (Schedule Of Notes Payable) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Total notes payable	$ 3,236	$ 825
Less current maturities	2,437	294
Long-term note payable	799	531
Unsecured Note [Member] | Note Payable To A Related Party [Member]
Debt Instrument [Line Items]
Total notes payable	836	825
Secured Debt [Member] | Secured Note Payable [Member]
Debt Instrument [Line Items]
Total notes payable	$ 2,400

Debt (Summary Of Aggregate Matu

Debt (Summary Of Aggregate Maturities) (Details) $ in Thousands	Dec. 31, 2018USD ($)
Debt [Abstract]
2019	$ 2,437
2020	90
2020	93
2021	616
Convertible notes, net	$ 3,236

Debt (Schedule Of Convertible N

Debt (Schedule Of Convertible Notes Payable) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Convertible notes, net	$ 837
Convertible Debt [Member]
Debt Instrument [Line Items]
Total principal balance	1,225
Less Unamortized discount	388
Convertible notes, net	$ 837
Convertible Debt [Member] | Convertible Notes Dated September 10, 2018 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	0.40%
Effective Interest Rate	8.30%
Maturity Date	Sep. 7, 2023
Total principal balance	$ 800
Convertible Debt [Member] | Convertible Note Dated September 19, 2018 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	0.57%
Effective Interest Rate	8.30%
Maturity Date	Sep. 19, 2023
Total principal balance	$ 425

Debt (Reconciliation Of Secured

Debt (Reconciliation Of Secured Contingent Obligation At Fair Value) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Debt [Abstract]
Secured contingent payment obligation, beginning of year	$ 15,896	$ 14,185
Proceeds from contingent payment obligation	4,000	1,000
Repayment
Change in fair value	5,661	711
Secured contingent payment obligation, end of year	$ 25,557	$ 15,896

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset transfers	$ 0	$ 0
Liabilities transfers	0	0
Fair value of note payable	3,000,000
Change in fair value	5,661,000	711,000
Secured Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Fair Value Disclosure	2,500,000
Change in fair value	$ 4,600,000
Secured Debt [Member] | Measurement Input, Discount Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.165
Secured Debt [Member] | Measurement Input, Discount Rate [Member] | Result of a Decrease [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.08
Secured Debt [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.025
Secured Debt [Member] | Measurement Input, Entity Credit Risk [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.08
Secured Debt [Member] | Measurement Input, Litigation Inherent Risk [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.06
Secured Debt [Member] | Measurement Input, Expected Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Risk free term	2 years
Minimum [Member] | Secured Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent obligation	$ 0
Contingent obligation, probability	0.00%
Maximum [Member] | Secured Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent obligation	$ 46,000,000
Contingent obligation, probability	35.00%
Probability-Eeighted Income Approach [Member] | Unsecured Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of note payable	$ 25,600,000	$ 15,900,000

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis) (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Secured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities	$ 25,557	$ 15,896
Available-For-Sale Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets		26
Restricted Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets		1,000
Quoted Prices In Active Markets (Level 1) [Member] | Secured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities
Quoted Prices In Active Markets (Level 1) [Member] | Available-For-Sale Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets		26
Quoted Prices In Active Markets (Level 1) [Member] | Restricted Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets		1,000
Significant Other Observable Inputs (Level 2) [Member] | Secured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities
Significant Other Observable Inputs (Level 2) [Member] | Available-For-Sale Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets
Significant Other Observable Inputs (Level 2) [Member] | Restricted Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets
Significant Unobservable Inputs (Level 3) [Member] | Secured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities	$ 25,557	15,896
Significant Unobservable Inputs (Level 3) [Member] | Available-For-Sale Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets
Significant Unobservable Inputs (Level 3) [Member] | Restricted Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets

Income Taxes And Tax Status (Na

Income Taxes And Tax Status (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Tax Credit Carryforward [Line Items]
Foreign income tax expense
Current tax provision or benefit	0	0
Deferred tax provision or benefit	$ 0	$ 0
Corporate tax rate	21.00%	34.00%
Operating loss carryforwards	$ 336,400,000
Operating loss carryforwards subject to expiration	323,500,000
Unrecognized tax benefits	927,000	$ 927,000	$ 1,370,000
Accrued interest or penalties	0	0
Income tax-related interest income, expense or penalties	0	0
Impact of the Tax Act	0	$ 41,646,000
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforward, Amount	$ 7,900,000
Minimum [Member]
Tax Credit Carryforward [Line Items]
Operating loss carryforwards, expiration	Dec. 31, 2019
Period subject to IRS examination	1998
Minimum [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward [Line Items]
Operating loss carryforwards, expiration	Dec. 31, 2019
Maximum [Member]
Tax Credit Carryforward [Line Items]
Operating loss carryforwards, expiration	Dec. 31, 2036
Period subject to IRS examination	2018
Maximum [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward [Line Items]
Operating loss carryforwards, expiration	Dec. 31, 2037
Convertible Debt [Member] | Promissory Notes [Member]
Tax Credit Carryforward [Line Items]
Unrecognized tax benefits	$ 100,000

Income Taxes And Tax Status (Sc

Income Taxes And Tax Status (Schedule of Effective Income Tax Rate Reconciliation) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Taxes And Tax Status [Abstract]
Tax benefit at statutory rate	$ (4,382,000)	$ (6,548,000)
State tax benefit	(897,000)	(674,000)
Impact of the Tax Act	0	41,646,000
Increase (decrease) in valuation allowance	5,304,000	(34,346,000)
Research and development credit	(51,000)	(129,000)
Other	26,000	51,000
Income Tax Expense (Benefit), Total

Income Taxes And Tax Status (_2

Income Taxes And Tax Status (Schedule of Deferred Tax Assets And Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Income Taxes And Tax Status [Abstract]
Net operating loss carry-forward	$ 84,192	$ 82,168
Research and development credit	7,879	8,051
Stock compensation	1,027	1,248
Patents and other	1,495	1,427
Contingent payment obligation	2,842	1,409
Inventories	249
Fixed assets	25	25
Accrued liabilities	146	49
Deferred rent and lease liabilities	46	20
Charitable contributions	5	7
Deferred revenue		5
Capital loss carry-forward	3	3
Warranty reserve	4	2
Bad debt expense		1
Deferred tax assets, gross	97,913	94,415
Less valuation allowance	(97,816)	(94,415)
Net deferred tax asset	97
Convertible debt	(97)
Deferred tax liabilities, gross	(97)
Net deferred tax asset

Income Taxes And Tax Status (_3

Income Taxes And Tax Status (Schedule of Unrecognized Tax Benefits Roll Forward) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Taxes And Tax Status [Abstract]
Unrecognized tax benefits, beginning of year	$ 927	$ 1,370
Impact of the Tax Act		(443)
Unrecognized tax benefits, end of year	$ 927	$ 927

Commitments And Contingencies_2

Commitments And Contingencies (Narrative) (Details)

Mar. 10, 2017item

Jan. 31, 2019USD ($)

Mar. 31, 2017item

Jan. 31, 2017item

Mar. 31, 2016item

Dec. 31, 2015item

Aug. 31, 2015item

Dec. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Mar. 31, 2019USD ($)

Mar. 14, 2019USD ($)

Oct. 31, 2018USD ($)

Aug. 31, 2017USD ($)

Commitments and Contingencies [Line Items]

Operating lease

$ 908,000

Rent expense

500,000

$ 600,000

Qualcomm v. ParkerVision (Federal Patent Court in Germany) [Member]

Commitments and Contingencies [Line Items]

Statutory fees and costs

100,000

ParkerVision vs. Qualcomm, Inc. [Member]

Commitments and Contingencies [Line Items]

Number of petitions | item

10

Number of petitions outstanding | item

6

Number of patents allegedly infringed upon seeking invalidation | item

3

Number of patents allegedly infringed upon | item

11

Number of petitions denied institution of trial | item

3

Number of patents found infringed upon | item

3

Number of patents found not infringed upon | item

2

ParkerVision V. Apple And Qualcomm (ITC) [Member]

Commitments and Contingencies [Line Items]

Number of patents allegedly infringed upon | item

4

Number of patents dismissed | item

1

3

ParkerVision v. Apple and Qualcomm (Middle District of Florida) [Member]

Commitments and Contingencies [Line Items]

Number of patents allegedly infringed upon | item

4

ParkerVision v. Apple (Munich, Germany) [Member]

Commitments and Contingencies [Line Items]

Estimated loss

$ 100,000

Intel v. ParkerVision (Federal Patent Court in Germany) [Member]

Commitments and Contingencies [Line Items]

Estimated loss

$ 0

$ 100,000

$ 100,000

Subsequent Event [Member] | ParkerVision v. LG Electronics [Member]

Commitments and Contingencies [Line Items]

Estimated loss

$ 60,000

Bond

$0.06

Subsequent Event [Member] | ParkerVision v. Apple (Munich, Germany) [Member]

Commitments and Contingencies [Line Items]

Estimated loss

$ 100,000

Attorney fees

$ 200,000

Subsequent Event [Member] | ParkerVision v. Apple (Munich, Germany) Apple II Case [Member]

Commitments and Contingencies [Line Items]

Estimated loss

$ 140,000

Subsequent Event [Member] | Intel v. ParkerVision (Federal Patent Court in Germany) [Member]

Commitments and Contingencies [Line Items]

Attorney fees

$ 100,000

Corporate Office [Member] | Jacksonville Florida [Member]

Commitments and Contingencies [Line Items]

Lease End Date

Jul. 31, 2019

Wireless Design Facility [Member] | Lake Mary Florida [Member]

Commitments and Contingencies [Line Items]

Lease End Date

Nov. 30, 2022

Warehouse And Production Facility [Member] | Jacksonville Florida [Member]

Commitments and Contingencies [Line Items]

Lease End Date

Jul. 31, 2020

Lake Mary, Florida Facility [Member]

Commitments and Contingencies [Line Items]

Operating lease

$ 700,000

Lease liability

$ 200,000

Commitments And Contingencies_3

Commitments And Contingencies (Summary Of Facilities Under Lease Agreements) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Property Subject to or Available for Operating Lease [Line Items]
Lease expense	$ 163
Corporate Office [Member] | Jacksonville Florida [Member]
Property Subject to or Available for Operating Lease [Line Items]
Lease Start Date	Jul. 15, 2018
Lease End Date	Jul. 31, 2019
Lease expense	$ 31
Wireless Design Facility [Member] | Lake Mary Florida [Member]
Property Subject to or Available for Operating Lease [Line Items]
Lease Start Date	Jul. 1, 2017
Lease End Date	Nov. 30, 2022
Renewal options remaining	36 months
Lease expense	$ 13
Warehouse And Production Facility [Member] | Jacksonville Florida [Member]
Property Subject to or Available for Operating Lease [Line Items]
Lease Start Date	Jul. 1, 2017
Lease End Date	Jul. 31, 2020
Lease expense	$ 2

Commitments And Contingencies_4

Commitments And Contingencies (Schedule Of Future Minimum Lease Payments For Capital Leases And Operating Leases) (Details) $ in Thousands	Dec. 31, 2018USD ($)
Commitments And Contingencies [Abstract]
Operating leases 2019	$ 372
Operating leases 2020	191
Operating leases 2021 and thereafter	345
Operating Leases Total	908
Capital Leases 2019	2
Capital Leases 2020	1
Capital Leases, Total	$ 3

Stock Authorization And Issua_3

Stock Authorization And Issuance (Narrative) (Details)	Oct. 30, 2018shares	Mar. 26, 2018item$ / sharesshares	Oct. 17, 2017USD ($)shares	Mar. 30, 2016$ / shares	Sep. 30, 2018USD ($)$ / sharesshares	Jul. 31, 2018USD ($)$ / sharesitemshares	Feb. 28, 2017item$ / sharesshares	Nov. 30, 2016USD ($)	Mar. 31, 2016	May 31, 2018USD ($)$ / sharesshares	Mar. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Jun. 30, 2018USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesitemshares	Jun. 12, 2018shares	Oct. 31, 2017USD ($)shares	Aug. 14, 2017USD ($)	Jul. 11, 2017shares	Jul. 10, 2017shares	Dec. 31, 2016USD ($)	Nov. 17, 2005shares
Stock Authorization And Issuance [Line Items]
Preferred Stock, Shares authorized														15,000,000								100,000
Preferred Stock, Shares outstanding														0
Common stock, shares authorized												30,000,000		75,000,000	30,000,000	40,000,000			30,000,000	20,000,000
Shelf, authorized shares	75,000,000
Exercise price per warrant | $ / shares														$ 0.39
Warrants | $												$ 826,000		$ 1,810,000	$ 826,000
Warrants expired														70,000	0
Price per share of warrants expired | $ / shares														$ 3.25
Sale of common stock, number of shares														2,000,000
Sale of common stock | $														$ 5,276,000	$ 13,679,000
Shares of common stock issued upon exercise of warrants														13,300,000
Estimated fair market value | $												800,000		$ 1,800,000	800,000
Warrants expiration period														5 years
Proceeds from warrants exercised | $														$ 0	$ 0
Issuance of stock to consultants, shares															300,000
Issuance of stocks to consultants | $															$ 400,000
Number of consultants | item															2
Convertible Debt [Member]
Stock Authorization And Issuance [Line Items]
Shares reserved for issuance														6,000,000
Warrants, Options And Unvested RSUs [Member]
Stock Authorization And Issuance [Line Items]
Shares reserved for issuance														14,500,000
Pre-funded Warrant [Member]
Stock Authorization And Issuance [Line Items]
Sale of common stock, number of shares														2,100,000
Shares of common stock issued upon exercise of warrants														2,900,000
Brickell [Member]
Stock Authorization And Issuance [Line Items]
Warrants to purchase common stock														5,000,000
Warrant term														5 years
Exercise price per warrant | $ / shares														$ 0.16
Common Stock [Member]
Stock Authorization And Issuance [Line Items]
Sale of common stock | $														$ 45,000	$ 73,000
Shareholder Approved Equity Compensation Plans [Member]
Stock Authorization And Issuance [Line Items]
Shares reserved for issuance														300,000
Offering Under PIPE Agreement [Member]
Stock Authorization And Issuance [Line Items]
Warrants to purchase common stock					1,900,000	2,000,000
Legal fees | $					$ 50,000
Warrant term						5 years
Number of tranches | item						2
Offering Under PIPE Agreement [Member] | Share-based Compensation Award, Tranche One [Member]
Stock Authorization And Issuance [Line Items]
Warrants to purchase common stock					2,500,000	2,500,000
Exercise price per warrant | $ / shares					$ 0.01	$ 0.01
Offering Under PIPE Agreement [Member] | Share-based Compensation Award, Tranche Two [Member]
Stock Authorization And Issuance [Line Items]
Aggregate offering price | $					$ 1,000,000	$ 1,000,000
Warrants to purchase common stock					2,500,000	2,500,000
Exercise price per warrant | $ / shares					$ 0.74	$ 0.74
Director Stock Purchase [Member]
Stock Authorization And Issuance [Line Items]
Number of directors | item							1
Sale of common stock, number of shares							100,000
Sale of stock price per share | $ / shares							$ 2.11
Director Stock Purchase [Member] | Director [Member]
Stock Authorization And Issuance [Line Items]
Number of directors | item		3
Director Stock Purchase [Member] | Director [Member] | Common Stock [Member]
Stock Authorization And Issuance [Line Items]
Sale of common stock, number of shares		200,000
Sale of stock price per share | $ / shares		$ 0.83
Offerings under ATM [Member]
Stock Authorization And Issuance [Line Items]
Legal fees | $										$ 100,000	$ 400,000	$ 200,000
Shelf, duration								3 years
Sale of common stock, number of shares										1,400,000	4,100,000	2,100,000
Sale of common stock | $										$ 1,100,000	$ 9,600,000	$ 3,000,000
Sale of stock price per share | $ / shares										$ 0.87	$ 2.46	$ 1.50			$ 1.50
Offerings under ATM [Member] | Maximum [Member]
Stock Authorization And Issuance [Line Items]
Aggregate offering price | $								$ 15,000,000										$ 4,400,000
Offerings under ATM [Member] | Maximum [Member] | Common Stock [Member]
Stock Authorization And Issuance [Line Items]
Aggregate offering price | $																					$ 10,000,000
Offerings under Equity Line Agreement [Member]
Stock Authorization And Issuance [Line Items]
Shares reserved for issuance													16,900,000
Legal fees | $															$ 40,000
Shelf, duration			30 months
Sale of common stock under commitment fee			0.3
Sale of common stock, number of shares													2,900,000		770,000
Sale of common stock | $													$ 2,000,000		$ 960,000
Sale of stock price per share | $ / shares													$ 0.50
Purchase notice			30.00%											19.99%
Purchase price per share, VWAP			97.00%
Exchange cap | $ / shares														$ 1.48
Offerings under Equity Line Agreement [Member] | Maximum [Member]
Stock Authorization And Issuance [Line Items]
Aggregate offering price | $			$ 20,000,000														$ 500,000
Aggregate offering shares																	4,000,000
Rights Agreement [Member]
Stock Authorization And Issuance [Line Items]
Redemption price | $ / shares														$ 0.01
Exercise price per warrant | $ / shares				$ 14.50
Post reserve split ratio				0.1
Threshold percentage at which rights separte from common stock									15.00%

Stock Authorization And Issua_4

Stock Authorization And Issuance (Summary Of Equity Offerings) (Details) - USD ($) $ / shares in Units, shares in Thousands	3 Months Ended		5 Months Ended	6 Months Ended	12 Months Ended
	May 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Equity Offerings [Line Items]
# of Common Shares/ Units Sold					$ 5,276,000	$ 13,679,000
Average Exercise Price Per Warrant					$ 0.39
Net Proceeds					$ 0	0
Offering Under PIPE Agreement [Member] | July 2018 and September 2018 [Member]
Equity Offerings [Line Items]
Number of warrants issued					10,000
Average Exercise Price Per Warrant					$ 0.38
Net Proceeds					$ 1,901,000
Director Stock Purchase [Member] | March 2018 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold					$ 217,000
Average Price per Share/Unit					$ 0.83
Net Proceeds					$ 180,000
Director Stock Purchase [Member] | February 24, 2017 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold						$ 81,000
Average Price per Share/Unit			$ 2.11			$ 2.11
Net Proceeds						$ 170,000
Offerings under ATM [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold	$ 1,100,000	$ 9,600,000	$ 3,000,000
Offerings under ATM [Member] | March - May 2018 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold					$ 1,359,000
Average Price per Share/Unit					$ 0.87
Net Proceeds					$ 1,148,000
Offerings under ATM [Member] | August - December 2017 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold						$ 2,119,000
Average Price per Share/Unit			$ 1.50			$ 1.50
Net Proceeds						$ 2,970,000
Offerings under ATM [Member] | January - March 2017 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold						$ 4,072,000
Average Price per Share/Unit			2.46			$ 2.46
Net Proceeds						$ 9,581,000
Offerings under Equity Line Agreement [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold				$ 2,000,000		960,000
Offerings under Equity Line Agreement [Member] | January - June 2018 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold					$ 2,940,000
Average Price per Share/Unit					$ 0.70
Net Proceeds					$ 2,047,000
Offerings under Equity Line Agreement [Member] | October - December 2017 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold						$ 773,000
Average Price per Share/Unit			$ 1.29			$ 1.29
Net Proceeds						$ 958,000

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, net of estimated forfeitures	$ 200,000
Expected weighted average period to recognize the compensation cost, in years	1 year
2008 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant	19,673
Maximum number of shares per employee	5,000
Number of shares authorized	50,000
2000 Performance Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant	0
Number of shares authorized	500,000
2011 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant	296,952
Maximum number of shares per employee	150,000
Number of shares authorized	3,000,000
Restricted Stock Award And Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested fair value	$ 300,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value of option shares granted	$ 0.46	$ 1.52
Fair market value of vested shares	$ 500,000	$ 200,000
Intrinsic value of options exercised	$ 0	$ 0
Minimum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Maximum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Non Employee [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year

Share-Based Compensation (Sched

Share-Based Compensation (Schedule Of Share-Based Compensation Expense Included In Statements Of Operations) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 1,050	$ 2,164
Research And Development Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	169	564
Selling, General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	831	$ 1,600
Restructuring Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 50

Share-Based Compensation (Summa

Share-Based Compensation (Summary Of Restricted Stock Activity) (Details) - Restricted Stock Award And Restricted Stock Unit [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested at beginning of year, Shares | shares	521
Granted, Shares | shares	221
Vested, Shares | shares	(629)
Forfeited, Shares | shares	(99)
Non-vested at end of year, Shares | shares	14
Non-vested at beginning of year, Weighted-Average Grant-Date Fair Value | $ / shares	$ 1.98
Granted, Weighted Average Grant Date Fair Value | $ / shares	0.37
Vested, Weighted Average Grant Date Fair Value | $ / shares	1.42
Forfeited, Weighted Average Grant Date Fair Value | $ / shares	1.94
Non-vested at end of year, Weighted-Average Grant-Date Fair Value | $ / shares	$ 1.98

Share-Based Compensation (Sum_2

Share-Based Compensation (Summary Of Option Activity) (Details) - Stock Options [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Shares, Beginning of year | shares	1,007
Granted, Shares | shares	507
Exercised, Shares | shares
Forfeited, Shares | shares	(42)
Expired, Shares | shares	(244)
Outstanding, Shares, End of year | shares	1,228
Outstanding, Weighted Average Exercise Price, Beginning of year | $ / shares	$ 10.82
Granted, Weighted Average Exercise Price | $ / shares	0.60
Exercised, Weighted Average Exercise Price | $ / shares
Forfeited, Weighted Average Exercise Price | $ / shares	1.59
Expired, Weighted Average Exercise Price | $ / shares	9.96
Outstanding, Weighted Average Exercise Price, End of year | $ / shares	$ 7.09
Outstanding, Weighted Average Remaining Contractual Term	4 years 7 months 28 days
Outstanding, Aggregate Intrinsic Value | $
Vested and expected to vest at end of year, shares | shares	849
Vested and expected to vest at end of year, weighted average exercise price | $ / shares	$ 9.98
Vested and expected to vest at end of year, weighted average remaining contractual term	3 years 8 months 23 days
Vested and expected to vest at end of year, aggregate intrinsic value | $

Share-Based Compensation (Sum_3

Share-Based Compensation (Summary Of Valuation Assumptions) (Details) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected annual dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option term	5 years	4 years
Expected volatility factor	68.80%	98.00%
Risk-free interest rate	2.60%	1.70%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option term	6 years
Expected volatility factor	93.60%	100.80%
Risk-free interest rate	3.00%	2.20%

Share-Based Compensation (Sum_4

Share-Based Compensation (Summary Of Options And Warrants By Exercise Price Range) (Details) - Stock Options [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Options Outstanding
Number Outstanding | shares	1,228
Wtd. Avg. Exercise Price	$ 7.09
Wtd. Avg. Remaining Contractual Life	4 years 7 months 28 days
Options Vested
Number Exercisable | shares	849
Wtd. Avg. Exercise Price	$ 9.98
Wtd. Avg. Remaining Contractual Life	3 years 8 months 23 days
$0.60 - $1.23 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Excercise price minimum	$ 0.60
Exercise price maximum	$ 1.23
Options Outstanding
Number Outstanding | shares	502
Wtd. Avg. Exercise Price	$ 0.60
Wtd. Avg. Remaining Contractual Life	6 years 8 months 16 days
Options Vested
Number Exercisable | shares	127
Wtd. Avg. Exercise Price	$ 0.61
Wtd. Avg. Remaining Contractual Life	6 years 7 months 24 days
$1.80 - $13.20 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Excercise price minimum	$ 1.80
Exercise price maximum	$ 13.20
Options Outstanding
Number Outstanding | shares	459
Wtd. Avg. Exercise Price	$ 2.43
Wtd. Avg. Remaining Contractual Life	4 years 7 months 24 days
Options Vested
Number Exercisable | shares	455
Wtd. Avg. Exercise Price	$ 2.43
Wtd. Avg. Remaining Contractual Life	4 years 7 months 21 days
$13.80 - $22.60 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Excercise price minimum	$ 13.80
Exercise price maximum	$ 22.60
Options Outstanding
Number Outstanding | shares	28
Wtd. Avg. Exercise Price	$ 14.05
Wtd. Avg. Remaining Contractual Life	2 years 5 months 23 days
Options Vested
Number Exercisable | shares	28
Wtd. Avg. Exercise Price	$ 14.05
Wtd. Avg. Remaining Contractual Life	2 years 5 months 23 days
$23.80 - $38.80 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Excercise price minimum	$ 23.80
Exercise price maximum	$ 38.80
Options Outstanding
Number Outstanding | shares	230
Wtd. Avg. Exercise Price	$ 28.25
Wtd. Avg. Remaining Contractual Life	6 months 18 days
Options Vested
Number Exercisable | shares	230
Wtd. Avg. Exercise Price	$ 28.25
Wtd. Avg. Remaining Contractual Life	6 months 18 days
$45.10 - $45.10 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Excercise price minimum	$ 45.10
Exercise price maximum	$ 45.10
Options Outstanding
Number Outstanding | shares	9
Wtd. Avg. Exercise Price	$ 45.10
Wtd. Avg. Remaining Contractual Life	1 year 11 months 16 days
Options Vested
Number Exercisable | shares	9
Wtd. Avg. Exercise Price	$ 45.10
Wtd. Avg. Remaining Contractual Life	1 year 11 months 16 days

Restructuring Charges (Narrativ

Restructuring Charges (Narrative) (Details)	Aug. 31, 2018employee
Lake Mary, Florida Facility [Member]
Restructuring Cost and Reserve [Line Items]
Employees	30

Restructuring Charges (Schedule

Restructuring Charges (Schedule Of Restructuring Charges) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Restructuring Charges [Abstract]
One-time termination benefits	$ 135
Lease expense	163
Asset impairment charges	375
Other	17
Restructuring charges	$ 690

Restructuring Charges (Schedu_2

Restructuring Charges (Schedule Of Accrued Reserve) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018
Termination Benefits
Termination benefits recognized	$ 690
One-time Termination Benefits [Member]
Termination Benefits
Beginning of period
Termination benefits recognized	135
Termination benefits settled	(115)
End of period	20
Leases Payable
Beginning of period
Settlements	(115)
End of period	20
Long-Term Lease Payable
Lease payable			$ 20
Lease Payable [Member]
Termination Benefits
Beginning of period
Termination benefits settled	(48)
End of period	177
Leases Payable
Beginning of period
Present value of future minimum lease payments less estimated future sublease rentals, net of deferred rent of $62	182
Settlements	(48)
Change in estimate	43
End of period	177
Long-Term Lease Payable
Lease payable			177
Current portion of lease liability			86
Long-term portion of lease liability			91
Deferred rent			$ 62

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Mar. 29, 2019	Dec. 31, 2018	Dec. 31, 2017	Mar. 31, 2019	Sep. 10, 2018	Mar. 26, 2018	Feb. 28, 2017
Related Party Transaction [Line Items]
Common stock, shares issued		28,677,000	21,222,000
Sterne, Kessler, Goldstein & Fox, PLLC [Member]
Related Party Transaction [Line Items]
Amount paid to related party		$ 30,000	$ 30,000
Board of Directors Chairman [Member]
Related Party Transaction [Line Items]
Sale of stock price per share							$ 2.11
Common stock, shares issued							0.1
Three Directors [Member]
Related Party Transaction [Line Items]
Sale of stock price per share						$ 0.83
Common stock, shares issued						200,000
Convertible Debt [Member] | Subsequent Event [Member]
Related Party Transaction [Line Items]
Conversion price				$ 0.25
Interest rate				8.00%
Promissory Notes [Member] | Convertible Debt [Member]
Related Party Transaction [Line Items]
Interest rate		8.00%
Promissory Notes [Member] | Convertible Debt [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Debt					$ 100,000
Promissory Notes [Member] | Convertible Debt [Member] | Board of Directors Chairman [Member]
Related Party Transaction [Line Items]
Debt					100,000
Promissory Notes [Member] | Convertible Debt [Member] | Director [Member]
Related Party Transaction [Line Items]
Debt					100,000
Promissory Notes [Member] | Convertible Debt [Member] | Stacie Wilf [Member]
Related Party Transaction [Line Items]
Debt					$ 100,000
Promissory Notes [Member] | Convertible Debt [Member] | Related Parties [Member]
Related Party Transaction [Line Items]
Conversion price					$ 0.40
Debt					$ 400,000
Promissory Notes [Member] | Unsecured Note [Member] | Sterne, Kessler, Goldstein & Fox, PLLC [Member]
Related Party Transaction [Line Items]
Amount paid to related party		$ 60,000	$ 70,000
Interest rate		8.00%
Maturity date		Mar. 31, 2020
Secured notes payable		$ 800,000
Debt		$ 800,000
Promissory Notes [Member] | Unsecured Note [Member] | Sterne, Kessler, Goldstein & Fox, PLLC [Member] | Subsequent Event [Member]
Related Party Transaction [Line Items]
Interest rate	8.00%
Maturity date	Mar. 31, 2020

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 29, 2019	Dec. 31, 2018	Sep. 30, 2018	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018
Subsequent Event [Line Items]
Proceeds from debt					$ 4,000	$ 1,000
Liabilities, Noncurrent		$ 27,285			27,285	16,495	$ 27,285
Convertible Debt [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from debt				$ 1,300
Term				5 years
Conversion price				$ 0.25
Interest rate				8.00%
Secured Debt [Member]
Subsequent Event [Line Items]
Proceeds from debt		$ 2,500			$ 4,000	$ 1,000	$ 18,000
Promissory Notes [Member] | Convertible Debt [Member]
Subsequent Event [Line Items]
Proceeds from debt			$ 1,300
Term					5 years
Interest rate		8.00%			8.00%		8.00%
Promissory Notes [Member] | Secured Debt [Member]
Subsequent Event [Line Items]
Interest rate		12.00%			12.00%		12.00%
Promissory Notes [Member] | Sterne, Kessler, Goldstein & Fox, PLLC [Member] | Secured Debt [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Interest rate	8.00%
Maturity date	Mar. 31, 2020
Amended Promissory Note [Member] | Sterne, Kessler, Goldstein & Fox, PLLC [Member] | Secured Debt [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Interest rate	4.00%
Maturity date	Apr. 30, 2022
Liabilities, Noncurrent	$ 650